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2 ABBREVIATIONS
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CIII, respiratory complex III (cytochrome bc1 complex) 
RISP, Rieske iron-sulfur protein (UQCRFS1) 
NAD+, Nicotinamide adenine dinucleotide, oxidized 
AOX, alternative oxidase 
NR, nicotinamide riboside 
mtDNA, mitochondrial DNA 
TCA cycle, tricarboxylic acid cycle (Kreb’s cycle) 
ATP, adenosine triphosphate 
NADH, Nicotinamide adenine dinucleotide, reduced 
GTP,  Guanosine triphosphate 
FADH, flavin adenine dinucleotide, reduced 
CI, complex I 
CII, complex II 
CIV, complex IV 
ETFDH, electron-transferring flavoprotein dehydrogenase 
ETF, electron-transferring flavoprotein 
ACAD, acyl-CoA dehydrogenase 
DHODH, dihydroorotate dehydrogenase 
SQOR, sulfide:quinone oxidoreductase 
PRODH, proline dehydrogenase 
CHDH, choline dehydrogenase 
GPD2, glycerol 3-phosphate dehydrogenase 
redox, reduction-oxidation 
Qo, quinol oxidation site 
Qi, quinone reduction site 
heme bL, low-potential heme b 
heme bH, high-potential heme b 
AAA, ATPases associated with diverse cellular activities 
ROS, reactive oxygen species 
LHON, Leber Hereditary Optic Neuropathy 
AMPK, AMP-activated protein kinase 
SIRT1, sirtuin 1 
PPARα, peroxisome proliferator-activated receptor alpha 
PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
AICAR,  5-aminoimidazole-4-carboxamide ribonucleotide 
MELAS, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes 
NADPH, nicotinamide adenine dinucleotide phosphate, reduced 
NAMPT, nicotinamide phosphoribosyltransferase 
NMN, nicotinamide mononucleotide 
NRH, dihydro-nicotinamide riboside 
E%, % of energy 
P, postnatal day 
NAAD, nicotinic acid adenine dinucleotide 
FDR, false-discovery rate 
ACLY, ATP citrate lyase 
EPR, electron paramagnetic resonance 
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3 ABSTRACT
Mitochondrial disorders are rare diseases but collectively the most frequent group of inborn 
errors of metabolism. These disorders are genetically and phenotypically heterogenous and 
can manifest in any organ of the body with onset at any age. Mitochondrial functions are 
also diverse with the ATP production via the oxidative phosphorylation (OXPHOS) being 
the most notable. At the center of the OXPHOS machinery is the respiratory complex III 
(CIII, cytochrome bc1 complex). CIII deficiency in GRACILE syndrome belonging to the 
Finnish disease heritage causes a neonatal-lethal hepatorenal disease. The primary cause of 
GRACILE syndrome is a c.A232G (p.S78G) mutation in the BCS1L gene, which encodes 
a translocase required for Rieske Fe-S protein (RISP, UQCRFS1) incorporation into CIII. 
Homozygous Bcs1lp.S78G mice bearing the GRACILE syndrome mutation recapitulate the 
human syndrome, but unlike the patients they have a short asymptomatic period and 
relatively longer lifespan giving a window for therapeutic interventions. In this thesis 
project, we studied two potential therapies aiming to improve dysfunctional mitochondria 
in Bcs1lp.S78G mice: ketogenic diet and NAD+ repletion. We also utilized an alternative 
oxidase (AOX) transgene to bypass the electron-transfer blockade at CIII.
Ketogenic diets are low-carbohydrate high-fat diets causing nutritional ketosis. They have 
been proposed to induce a beneficial starvation-like adaptive mitochondrial response 
involving increased mitochondrial biogenesis. Bcs1lp.S78G mice tolerated the carbohydrate 
restriction of ketogenic diet, were able to utilize dietary fat as the main energy source and 
developed ketosis. Ketogenic diet attenuated the hepatic CIII assembly defect, increased 
CIII activity and corrected mitochondrial structural aberrations. Our results suggested 
that these changes were not due to increased mitochondrial biogenesis. In line with the 
improved CIII function, Bcs1l mutant mice showed attenuated hepatopathy as shown 
by delayed liver fibrosis, inhibited stellate cell activation and hepatic progenitor cell 
response, decreased cell death and plasma liver enzyme activities. Liver transcriptomics 
and subsequent histochemical analyses suggested altered macrophage activation and a 
normalizing effect by ketogenic diet.
In the second study, we characterized NAD+ metabolism in Bcs1lp.S78G mice. We found 
transcriptionally repressed NAD+ de novo biosynthesis and decreased hepatic NAD+ 
concentration. Changes in NAD+ consuming processes did not explain the decreased NAD+ 
levels. Aiming to replete the NAD+ levels, we fed the Bcs1lp.S78G mice a NAD+ precursor 
nicotinamide riboside (NR). In contrast to previous studies on mitochondrial myopathy 
models and mouse models with secondary mitochondrial dysfunctions, the hepatic 
NAD+ depletion of Bcs1lp.S78G mice was refractory to NR supplementation and the disease 
progression was unaltered. Cellular NAD+ levels regulate mitochondrial functions via 
sirtuin deacetylases, which are the main targets of NAD+ repletion therapies. Investigation 
of the upstream effectors of sirtuins showed that a starvation-like metabolic state of 
Bcs1lp.S78G mice is linked to AMP kinase and cAMP signaling, which likely counterbalances 
the repressive effect of decreased NAD+ levels on the activity of SIRT1 and SIRT3.
In the third study, we introduced Ciona intestinalis AOX transgene into the Bcs1lp.S78G mice. 
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AOXs are non-mammalian enzymes that can bypass a blockade of the CIII-CIV segment 
of the respiratory electron transfer. The AOX-expressing Bcs1lp.S78G mice were viable, and 
their CIII-deficiency stimulated AOX-mediated respiration in isolated mitochondria. 
AOX expression tripled the median lifespan of Bcs1lp.S78G mice from 200 to 600 days. The 
extension of the lifespan was predominantly due to the complete prevention of late-onset 
cardiomyopathy. The effects of AOX were tissue specific. In the heart of Bcs1lp.S78G mice, it 
preserved normal tissue structure and function, mitochondrial morphology, respiratory 
electron transfer, and wild-type-like transcriptome. In contrast, AOX only minimally 
affected the late-stage liver disease. Whereas, in the kidneys, AOX normalized an atrophic 
kidney phenotype and some histological lesions but it did not normalize kidney function 
or cause global normalization of transcriptome changes. Our results suggest tissue-specific 
thresholds of CIII deficiency for in vivo AOX-mediated respiration in CIII deficiency. 
Moreover, our study demonstrates the value of AOX as a research tool to dissect the 
pathogenesis of CIII deficiency.
During our investigations, we observed approximately 5-fold difference in the lifespan 
of the Bcs1lp.S78G mice on two closely related congenic backgrounds. In the fourth study, 
we tracked the difference to a spontaneous homoplasmic mitochondrial DNA (mtDNA) 
variant (mt-Cybp.D254N) in an isolated congenic Lund University mouse colony. The variant 
changes a highly conserved negative amino acid residue in the only mtDNA-encoded 
subunit of CIII, cytochrome b (MT-CYB). A crossbreeding experiment utilizing the 
maternal inheritance of mtDNA verified the novel variant as the determinant of the 
survival difference. Functional studies showed that the variant exacerbated complex III 
deficiency in all assessed tissues. In otherwise wild-type mice, it also decreased cardiac 
CIII activity, caused a slight disturbance in mitochondrial bioenergetics, and decreased 
whole-body energy expenditure. Molecular dynamics simulations and their verification 
in isolated mutagenized Rhodobacter capsulatus cytochrome bc1 complex showed that the 
mt-Cybp.D254N variant restricts the mobility of RISP head domain movement.  
In summary, these studies provided novel mechanistic and therapeutic insights into CIII 
deficiency at genetic, molecular, and metabolic level. The results highlight the importance 
of knowing the underlying tissue-specific pathology and metabolic adaptations when 
designing therapies for mitochondrial diseases. The genetic epistasis between Bcs1lp.S78G 
and mt-Cybp.D254N also highlights the role of mitochondrial DNA background as a modifier 
of mitochondrial disease phenotypes.
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4 TIIVISTELMÄ
Mitokondriotaudit ovat harvinaissairauksia, jotka kuitenkin ryhmänä muodostavat 
yleisimmän synnynnäisten aineenvaihduntahäiriöiden joukon. Mitokondriotautien 
mutaatioiden ja oireiden kirjo on erittäin laaja. Mitokondriotauti voi ilmetä lähes 
missä elimessä ja missä iässä tahansa. Mitokondriot ovat soluelimiä, joilla on lukuisia 
välttämättömiä tehtäviä. Näistä tunnetuin on ATP:n tuotanto oksidatiivisen fosforylaation 
avulla. Yksi keskeisistä entsyymeistä oksidatiivisessa fosforylaatiossa on hengitysketjun 
kompleksi III (sytokromi bc1 -kompleksi). Suomalaiseen tautiperintöön kuuluvassa 
GRACILE-oireyhtymässä kompleksi III:n puutos aiheuttaa vastasyntyneiden kuolemaan 
johtavan maksa- ja munuaistaudin. Oireyhtymän aiheuttaa homotsygoottinen c.A232G-
pistemutaatio (proteiinissa Ser78Gly) BCS1L-geenissä. BCS1L-proteiini on välttämätön 
Rieske rauta-rikki -proteiinin (RISP, UQCRFS1) kuljetukselle kompleksi III:een. Myös 
geneettisesti muokatuilla hiirillä homotsygoottinen Bcs1lp.S78G mutaatio aiheuttaa GRACILE-
oireyhtymän kaltaisen taudin. Potilaisten poiketen mutanttihiirillä on lyhyt syntymän 
jälkeinen oireeton jakso ennen taudin puhkeamista, mikä mahdollistaa hoitokokeiden 
aloittamisen jo ennen taudin puhkeamista. Tämän väitöskirjan tutkimuksissa tutkimme 
kahta mahdollista hoitoa mitokondrioiden toiminnan kohentamiseksi GRACILE-
oireyhtymän hiirimallissa: ketogeenistä ruokavaliota ja solujen NAD+-määrän 
(nikotiiniamidiadeniinidinukelotidi) lisäämistä. Tutkimme myös kompleksi III:n 
puutoksen ohittamista vaihtoehtoista oksidaasia (AOX, alternative oxidase) ilmentävän 
siirtogeenin avulla.
Ketogeeniset ruokavaliot sisältävät erittäin niukasti hiilihydraatteja ja runsaasti rasvaa, 
mikä aiheuttaa ketoosin eli ketoaineiden lisääntymisen veressä. Ketogeenisen ruokavalion 
on esitetty käynnistävän osittaisen paastovasteen, johon liittyy mitokondrioiden toiminnan 
tehostuminen ja niiden lisääntynyt uudistuotanto. Koska Bcs1lp.S78G-mutanttihiiret 
sopeutuivat ketogeeniseen ruokavalioon, ne ilmeisesti pystyivät hyödyntämään tehokkaasti 
rasvahappoja ja ketoaineita pääasiallisena energianlähteenä. Ketogeenisellä ruokavaliolla 
kompleksi III:een sitoutuneen RISP:n määrä lisääntyi mutanttihiiriillä, kuten myös 
kompleksi III:n aktiivisuus maksan mitokondrioissa. Nämä muutokset näkyivät myös 
maksan mitokondrioiden rakenteen normalisoitumisena. Tuloksemme viittasivat siihen, 
että mitokondrioiden toiminnan ja rakenteen parantuminen ei liittynyt lisääntyneeseen 
mitokondrioiden uudistuotantoon. Ketogeenisen ruokavalio hidasti merkittävästi 
maksataudin etenemistä, mikä näkyi muun muassa vähentyneenä stellaatti- ja ovaalisolujen 
aktivoitumisena, sekä vähentyneenä maksan sidekudostumisena. Myös maksaentsyymien 
aktiivisuudet plasmassa alenivat mutanttihiirillä. Maksan transkriptomiikka ja 
immunohistokemialliset värjäykset viittasivat siihen, että ketogeeninen ruokavalio vaikutti 
makrofagien toimintaan.
Väitöskirjan toisessa osatyössä tutkimme Bcs1lp.S78G-hiirten NAD+-aineenvaihduntaa. 
Havaitsimme, että mutanttihiirillä NAD+-tuotannosta vastaavien geenien ilmentyminen 
oli vähentynyt kuten myös maksan NAD+-pitoisuus. Muutokset NAD+:tä kuluttavissa 
aineenvaihduntaprosesseissa eivät selittäneet NAD+-pitoisuuden vähenemää. Syötimme 
Bcs1lp.S78G-hiirille NAD+:n esiastetta nikotiiniamidiribosidiä (NR) korjataksemme 
11
puutoksen. Poiketen aiemmista tutkimuksista, joissa NR:llä on ollut parantava vaikutus 
mitokondriaalisten lihastautien hiirimalleissa, NR ei vaikuttanut Bcs1lp.S78G-hiirten 
taudinkuvaan. NR ei myöskään vaikuttanut hoidon päätepisteessä mitattuun maksan 
NAD+-pitoisuuteen. Solujen NAD+-määrää kohentavien hoitojen yleinen tavoite on tehostaa 
NAD+:sta riippuvaisten deasetylaasien, sirtuiinien, aktiivisuutta. Tutkimme sirtuiinien 
NAD+:sta riippumattomia säätelymekanismeja ja havaitsimme, että mutanttihiirten 
nälkiintymistila aktivoi AMP-kinaasia ja cAMP-signalointia, jotka tunnetusti aktivoivat 
sirtuiini 1:tä ja 3:sta. Nämä muutokset oletettavasti kompensoivat vähentyneen NAD+-
määrän mahdollisia haitallisia vaikutuksia.
Kolmannessa osatyössä siirsimme Ciona intestinalis -vaippaeläimen AOX:ia koodaavan 
geenin Bcs1lp.S78G-hiiriin. AOX:it ovat nisäkkäiltä puuttuvia mitokondrioiden entsyymejä, 
jotka voivat ohittaa soluhengityksen tukoksen kompleksi III:n tai IV:n kohdalla. AOX ei 
ollut haitallinen Bcs1lp.S78G-hiirille ja kompleksi III:n toimintavajaus sai sen aktivoitumaan 
eristetyissä hiiren mitokondrioissa. Bcs1lp.S78G-hiirille alkoi kehittyä 150 elinpäivän jälkeen 
sydänlihassairaus, mihin ne kuolivat keskimäärin 200 päivän iässä. AOX:ia ilmentäville 
mutanttihiirille ei kehittynyt lainkaan sydäntautia, ja niiden mediaanielinikä oli 600 päivää. 
AOX esti täysin sydäntautiin liittyvän sydämen laajentuman ja toiminnan heikkenemisen. 
Sydämen mitokondrioissa AOX korjasi soluhengityksen sekä mitokondrioiden rakenteen 
muutokset. Vastaava pelastavaa vaikutusta AOX:illa ei ollut maksatautiin 150-200 päivän 
ikäisillä Bcs1lp.S78G-hiirillä. Munuaisissa taas AOX osittain korjasi tai esti kudosrakenteen 
muutoksia, mutta vaikutti vain vähäisesti tämän elimen toimintaan. Tuloksemme osoittivat, 
että AOX:n vaikutukset ovat kudoksesta riippuvaisia kompleksi III:n puutoksessa ja että se 
on hyödyllinen työkaluksi kompleksi III:n tautimekanismien tutkimuksessa.
Tutkimustemme alkuvaiheessa huomasimme noin viisinkertaisen eron Bcs1lp.S78G-hiirten 
eliniässä kahden eri hiirikannan välillä. Väitöskirjan neljännessä osatyössä löysimme 
koko genomin sekvensoinnilla homoplasmiseen yhden nukleotidin muutokseen Lundin 
yliopiston hiirikannan mitokondrio-DNA:ssa. Muutos vaihtaa negatiivisesti varautuneen 
aspartaatin neutraaliiin asparagiiniin (D254N) sytokromi b -proteiinissa (MT-CYB). 
MT-CYB on kompleksi III:n alayksiköistä ainoa, jonka geeni sijaitsee mitokondrio-
DNA:ssa. Käyttäen hyväksi mitokondrio-DNA:n maternaalista periytymistä osoitimme 
mt-Cybp.D254N-variantin aiheuttavan Bcs1lp.S78G-hiirten varhaisen kuoleman n. kuukauden 
iässä. Kuten oletimme mt-Cybp.D254N pahensi Bcs1lp.S78G-hiirten kompleksi III:n puutosta 
kaikissa tutkimissamme kudoksissa. Yksinäänkin mt-Cybp.D254N vähensi sydämessä 
kompleksi III:n aktiivisuutta, aiheutti pienen häiriön hengitysketjun toiminnassa ja 
pienensi hiirten energiankulutusta. Kompleksi III:n rakenteen tietokonemallinnukset ja 
biofysikaaliset tutkimukset Rhodobacter capsulatus -bakteerin sytokromi bc1-kompleksissa 
osoittivat, että D254N-aminohappomuutos häiritsee RISP:n elektroneja siirtävän domeenin 
liikettä kompleksi III:ssa.
Tämän väitöskirjan tutkimukset tuottivat uutta tietoa kompleksi III:n puutoksen 
tautimekanismeista ja mahdollisista hoidoista. Tuloksemme osoittavat, että on tärkeää 
tuntea mitokondriotaudin kudoskohtaisia ja vaihtelevia aineenvaihduntamuutoksia 
suunniteltaessa hoitoja. Bcs1lp.S78G-mutaation ja mt-Cybp.D254N-variantin yhteisvaikutus 




An estimated two billion years ago, an engulfment of an ancient relative of α-proteobacterium 
by a host cell, putatively related to Asgard archaea, gave rise to the mitochondrion, a double 
membrane-enclosed organelle performing cellular respiration.1,2 This event evolved into a 
vital endosymbiosis that defines all eukaryotes from protists, fungi, and plants to animals.3 
How the tricarboxylic acid cycle (TCA cycle, also known as Kreb’s cycle) functions as a 
bioenergetic and biosynthetic hub, and how mitochondrial respiratory enzymes generate 
the electrochemical potential coupled to adenosine triphosphate (ATP) production were 
the seminal discoveries of the decades from 1930s to 1970s.4–6 Research during the past two 
decades has recognized mitochondria as vital players in many areas of cell signaling and 
metabolism.7 The identification of full human mitochondrial proteome is also essentially 
completed.8 However, of the more than 1000 mitochondrial proteins many still lack 
functional annotation. Meanwhile, modern genetics has allowed more and more monogenic 
mitochondrial diseases to be identified.9 Unfortunately, the treatments for mitochondrial 
diseases lack far behind the diagnostic capabilities, despite the fact that mitochondrial 
diseases are, as a group, the most common in-born errors of metabolism.9,10 Many 
multigenic globally epidemic chronic diseases such as cancer, obesity, obesity-associated 
metabolic syndrome, Alzheimer’s and Parkinson’s diseases, have also an inherent link to 
mitochondria, the organelles that affect essentially all aspects of cellular metabolism.11
At the heart of virtually all energy-transducing respiratory electron-transfer systems in 
bacteria and in the mitochondria of eukaryotes lies the cytochrome bc1 complex, also 
known as quinol-cytochrome c oxidoreductase and in the mitochondria as complex 
III (CIII).12 CIII catalyzes the oxidation of the lipid electron carrier ubiquinol (reduced 
coenzyme Q) to ubiquinone (oxidized coenzyme Q) while passing on electrons to the 
soluble electron carrier cytochrome c, a substrate for the terminal oxidase cytochrome c 
oxidase (complex IV, CIV), which reduces oxygen to water. During the electron transfer, 
the respiratory complexes I, III and IV translocate protons to generate an electrochemical 
potential required for ATP synthesis. In mammalian mitochondria, CIII is vital for the 
availability of oxidized coenzyme Q and for the whole respiratory electron transfer.  
CIII deficiencies are relatively rare mitochondrial diseases and most often caused by 
mutations in the MT-CYB and BCS1L genes.13  BCS1L encodes a mitochondrial inner-
membrane translocase required for the incorporation of the Rieske Fe-S protein (RISP, 
UQCRFS1) into CIII.13,14 This process is compromised in GRACILE syndrome due to 
a c.A232G (p.S78G) mutation in BCSL.15,16 GRACILE syndrome is a severe neonatal 
mitochondrial disease belonging to the Finnish disease heritage. The name of the syndrome 
derives from main clinical features: growth restriction, aminoaciduria, cholestasis, iron 
overload, lactic acidosis and early neonatal death.15,17 To study the pathogenesis and 
potential treatments of GRACILE syndrome, Prof. Fellman’s research group generated a 
patient mutation knock-in mouse model some ten years ago.18 Similarly to the patients, 
the homozygous Bcs1lp.S78G mutation causes early-onset hepatorenal disease with growth 
restriction in mice. This thesis project set out to study dietary and pharmacological 
interventions, and xenogenic alternative oxidase-mediated bypass of CIII in the Bcs1lp.S78G 
mice. During the process, we identified and studied a novel mtDNA variant acting as a 
modifier of the CIII deficiency caused by the Bcs1lp.S78G mutation. 
1 μm
Figure 1. An electron micrograph showing mitochondria (dark electron-dense structures) of 
different sizes and shapes in a renal proximal tubule cell. Several cristae (yellow arrowheads) 
can be observed in most of the mitochondria.
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6 REVIEW OF LITERATURE
6.1 Mitochondria
6.1.1 Structure and function of mitochondria
Mitochondria are double-membraned cellular organelles the size, shape, and abundance 
of which vary widely between different tissues, cell types, and metabolic states (Fig. 
1).19,20 The outer membrane is permeable to most small molecules while the folded inner 
membrane, heavily packed with the respiratory complexes, forms an impermeable barrier 
separating the mitochondrial matrix from the mitochondrial inner-membrane space and 
cytoplasm. The folds of the inner membrane are called cristae. Their presumed function is 
to maximize the surface area of the membrane and locally condense the electrochemical 
potential to maximize the efficacy of ATP production. Mitochondrial morphology is highly 
dynamic and responds to metabolic demands such as those induced by feeding, fasting, 
and mitochondrial defects.21 Furthermore, mitochondria are inter-connected organelles 
that form a mitochondrial network, and also physically interact with other organelles 
such as endoplasmic reticulum and lipid droplets. Mitochondrial fission and fusion events 
largely regulate the morphology of individual mitochondria but also the shape of the 
mitochondrial network.
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Mitochondria have their own small genome, and transcription, translation, and replication 
machineries.22 In humans, the mitochondrial DNA (mtDNA) encodes 22 transfer 
RNAs, 2 ribosomal RNAs, and 13 vital structural and catalytic subunits of respiratory 
complexes and ATP synthase. The nuclear DNA encodes the rest, the vast majority, of the 
mitochondrial proteins which are translated by cytoplasmic ribosomes and then imported 
into mitochondria. In every mitochondrion there can be multiple copies of mtDNA and in 
every cell hundreds to thousands of copies. 
6.1.2 Respiratory electron transfer and oxidative phosphorylation 
Mitochondria are best known for their function as highly efficient producers of ATP, a high-
energy compound that fuels cellular metabolism.7 Anaerobic glycolysis produces 2 ATP 
molecules per glucose, whereas the full oxidation of glucose through cellular respiration 
produces approximately 32 ATPs. Mitochondria achieve this by the serial reactions of the 
TCA cycle that generate the reduced cofactors NADH, GTP and FADH.7,23 Consequently, 
NADH and FADH serve as substrates for the respiratory electron transfer (Fig. 2). Complex 
I (CI), NADH dehydrogenase, oxidizes NADH to NAD+ with a subsequent reduction 
of the lipid electron carrier ubiquinone to ubiquinol (oxidized and reduced coenzyme 
Q, respectively). The TCA cycle enzyme complex II (CII), succinate dehydrogenase, 
oxidizes succinate to fumarate while reducing the integrated cofactor FAD to FADH and 
consequent electron transfer from FADH to ubiquinone. The next enzyme in the electron 
transfer process is CIII, which accepts electrons from ubiquinol and passes them on 
to the soluble electron carrier, cytochrome c. The terminal oxidase in the mammalian 
mitochondria is complex IV (CIV, cytochrome c oxidase), which oxidizes cytochrome 
c and reduces oxygen to water, the very reaction seen as cellular respiration. Three of 
these respiratory enzymes contribute to the generation of the electrochemical potential by 
translocating protons from the matrix to the inter-membrane space, CI, CIII and CIV. The 
electrochemical potential comprises two factors: the electric difference (electric potential) 
and pH difference (chemical potential) across the membrane. The backflow of protons 
at ATP synthase catalyzes the conversion of ADP and inorganic phosphate to ATP. The 
respiratory electron transfer (cellular respiration) that is coupled to the phosphorylation 
of ADP is termed oxidative phosphorylation (OXPHOS).24 
The initiation of respiratory electron transfer is not limited to CI and CII (Fig. 2). In many 
cells, several other mitochondrial inner-membrane enzymes also utilize ubiquinone 
or cytochrome c as an electron acceptor, and therefore contribute to OXPHOS. The 
electron-transferring flavoprotein dehydrogenase (ETFDH) serves as a hub for more than 
ten flavoproteins that transfer the electrons via the electron-transferring flavoprotein 
(ETF) to ETFDH, which then transfers the electrons to ubiquinone.25,26 The most 
notable ETFDH-linked enzymes are acyl-CoA dehydrogenases (ACADs) of the fatty 
acid oxidation. Disruption of the respiratory electron transfer renders mammalian cells 
auxotrophic for uridine.27,28 This is because the dihydroorotate dehydrogenase (DHODH) 





































Figure 2.  The mitochondrial respiratory electron transfer system. The arrows and e- (electrons) 
mark the direction of reducing equivalents.  Because of space limitations, some mitochondrial 
inner-membrane (MIM) enzymes (SQOR, GPDH, PRODH, CHDH, DHODH, and ETFDH) are 
placed outside the membrane. Abbreviations: Q, ubiquinone; QH2, ubiquinol; Cyt c
3+, oxidized 
cytochrome c; Cyt c2+, reduced cytochrome c; H+ proton; IMS, inner-membrane space; MIM, 
mitochondrial inner membrane.
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recognized respiratory enzymes include sulfide:quinone oxidoreductase (SQOR)29, proline 
dehydrogenase (PRODH)30, choline dehydrogenase (CHDH)31, and glycerol 3-phosphate 
dehydrogenase (GPD2)32. Like DHODH, these also connect to cellular respiration at the 
level of ubiquinone. Moreover, a mitochondrial intermembrane space sulfhydryl oxidase 
GFER, involved in oxidative protein folding, and sulfite oxidase (SUOX) directly reduce 
cytochrome c bypassing the ubiquinone pool and CIII.33,34
6.1.3 Role of mitochondria beyond bioenergetics
Mitochondria have many functions beyond the OXPHOS. The TCA cycle is not only 
needed to drive energy metabolism, but it is also an important source of precursors 
for many biosynthetic processes.7,23 As an example, the TCA cycle intermediate 
citrate serves as a carbon source for de novo lipogenesis while succinyl-CoA for heme 
biosynthesis. Mitochondria are also important for reduction-oxidation (redox) balance 
and compartmentalization of reducing equivalents.7,35 Without cellular respiration, 
glycolysis will lead to the accumulation of lactate and the reduced cofactor NADH. 
Some unicellular organisms can excrete lactate to environment, but in multicellular 
organisms prolonged whole-body anaerobic glycolysis leads to metabolic acidosis. Many 
vital biosynthetic processes occur partly in cytoplasm and partly in mitochondria. For 
instance, the mitochondrial enzyme ALAS1 initiates heme biosynthesis, but cytoplasmic 
enzymes catalyze the subsequent steps until the two finals steps that again take place 
in the mitochondria.36 Some rare eukaryote species that have lost respiratory enzymes 
during evolution still have mitochondrial remnants harboring the enzymes required for 
the biosynthesis of iron-sulfur clusters.37 For some metabolic processes, similar enzymes, 
yet encoded by different genes, exist in cytoplasm and mitochondria. As an example, folate 
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and methionine cycles operate in the cytoplasm and in the mitochondria with partial 
redundancy.38
Many important detoxification reactions also take place in mitochondria.7 The 
mitochondrial enzymes carbamoyl phosphate synthetase and  ornithine transcarbamoyl 
transferase link urea cycle to mitochondria. Urea cycle is a detoxification process, mainly 
in the liver and to some degree in the kidneys, whereby toxic ammonia from amino acid 
catabolism is converted to urea to be excreted via urine. Metabolism of sulfur-containing 
amino acids releases hydrogen sulfide, a highly toxic metabolite, which inhibits several 
heme proteins, including CIV.7,29 The physiological amounts of hydrogen sulfide generated 
by cellular catabolism are, however, efficiently detoxified by the respiratory enzyme SQOR. 
Mitochondria have been noted as a major source of cellular hydrogen peroxide, but 
according to recent findings they may also serve as a sink for hydrogen peroxide.39,40
Mitochondria interact with the rest of the cell in various ways.23,41 AMP-activated protein 
kinase (AMPK) senses insufficient OXPHOS capacity by monitoring cellular adenylate 
phosphorylation status to drive a suitable adaptive mitochondrial response.42 The TCA cycle 
metabolites such as acetyl-CoA are important for protein posttranslational modifications.23 
The respiratory electron transfer leaks some electrons directly to oxygen which leads to the 
production of superoxide, an oxygen radical. Superoxide is rapidly converted to hydrogen 
peroxide by superoxide dismutases.41 Superoxide and hydrogen peroxide were once thought 
to be only harmful byproducts of OXPHOS. However, nowadays hydrogen peroxide is 
recognized to be an important signaling molecule regulating for example angiogenesis 
and cellular differentiation.41 Perhaps the most dramatic mitochondria-derived signal is 
the initiation of apoptosis by cytochrome c release.43 
6.2 Respiratory complex III (CIII, cytochrome bc1 complex)
6.2.1 The Q cycle
CIII, or more generally cytochrome bc1 complex, is an evolutionarily ancient enzyme and 
its three catalytic subunits are highly conserved among bacteria and eukaryotes.12 In its 
simplest form, such as in Rhodobacter capsulatus, cytochrome bc1 complex contains only 
the key three catalytic subunits: RISP, cytochrome b and cytochrome c1. Higher organisms 
have gained additional subunits around these three vital catalytic components during 
evolution. The mammalian CIII comprises eleven subunits.13 The exact functions of the 
additional subunits remains largely unknown. 
Cytochrome bc1 complexes operate under the Q-cycle mechanism (Fig. 3).12,44 The cycle 
initiates at the quinol oxidation site (Qo) where the iron-sulfur cluster of RISP accepts the 
first electron from ubiquinol converting the ubiquinol to an unstable semiquinone. After 
this, the low potential heme b (heme bL) of cytochrome b accepts the second electron from 
the semiquinone, generating ubiquinone. RISP transfers the first electron to cytochrome c1, 
which then reduces the soluble electron carrier cytochrome c. The parallel electron transfer 
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through two heme centers of cytochrome b mediate the reduction of ubiquinone at the 
quinone reduction site (Qi). During the Q cycle, cytochrome bc1 both oxidizes ubiquinol 
to ubiquinone but also reduces ubiquinone to ubiquinol with the net reaction in the favor 
of ubiquinol oxidation. The steps of the Q cycle are coupled to the release of four protons 
into the mitochondrial inner-membrane space per ubiquinol oxidized.
6.2.2 CIII structure and assembly, and the role of BCS1L
The mammalian CIII is a homodimer with each monomer thought to comprise eleven 
subunits.45,46 However, according to a recent re-analysis of high-resolution crystal and 
cryo-electron microscopy structures, the eleventh subunit, a RISP N-terminal fragment, 
is shared between the monomers, making the dimer a 21-subunit entity.46 mtDNA encodes 
only one of the CIII subunits, MT-CYB. Nuclear DNA encodes the rest of the complex. 
Yeast studies have delineated the steps of CIII assembly, and all evidence suggests that 
the process is highly similar in mammals.13,47 The construction of CIII monomer starts 
from MT-CYB and its hemylation. At least three assembly factors (UQCC1, UQCC2 and 
UQCC3) take part in the initial steps of the process, most likely by stabilizing the pre-
complex. The dimerization of CIII is an early event and follows soon after incorporation 
of the core proteins (UQCRC1 and UQCRC2).47 The finals steps of CIII assembly are 
known in most detail and involve the insertion of the essential catalytic subunit RISP (Fig. 
4A).14 RISP is imported into mitochondria via the common TOM-TIM23 import system. 
In the matrix, RISP gains its iron-sulfur cluster with LYRM7 (Mzm1 in yeast) serving as 
a scaffold.48 Then, BCS1L translocates the partially or even fully folded RISP back to the 


















Figure 3.  Operation of Q cycle in cytochrome bc1 complexes. The three catalytic subunits are 
shown, and the flow of electrons are marked with red arrows. For clarity, only one monomer 
of the dimeric complex is shown. Abbreviations: RISP (UQCRSFS1), Rieske-iron sulfur protein; 
CYB, cytochrome b; CYC1, cytochrome c1; Cyt c, cytochrome c; QH2, quinol; Q, quinone; Qo 
quinol oxidation site; Qi, quinol reduction site; Fe-S, iron-sulfur cluster of RISP; bL, low-potential 
heme b of CYB; bH, high-potential heme b of CYB.
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BCS1L belongs to AAA family proteins (ATPases associated with diverse cellular activities) 
based on sequence similarity. BCS1L monomer has three domains: a transmembrane 
domain in the N-terminus followed by a unique BCS1L-specific domain, and ATPase 
domain similar to AAA-ATPases in the C-terminus (Fig. 4B).14 Yeast Bcs1 contains an 
internal mitochondrial targeting sequence but the same segment is not conserved in 
mammals.50 Recently, two groups independently determined the structure of yeast Bcs151 
and mouse52 BCS1L. Unlike other AAA-ATPases, which are typically hexamers and 
participate in protein unfolding and degradation,53 BCS1L is a heptamer that translocates 
a folded substrate utilizing a specialized airlock-type translocation mechanism.51,52 The 
uniqueness of BCS1L for the ability to translocate a partially of fully folded protein, while 
preserving mitochondrial inner membrane intactness and membrane potential, likely 
means that the RISP is its only substrate. 
After insertion into the complex, RISP goes through a proteolytic cleavage of the N-terminus 
containing the mitochondrial targeting sequence.54,55 The core proteins UQCRC1 and 
UQCRC2 which are homologous to matrix-processing peptidase likely perform the 
cleavage.55,56 Intriguingly, one of the N-terminus fragments forms the eleventh subunit of 
CIII in mammals but not in yeast.46,54 A study characterizing the CIII-interacting protein 








































Figure 4. Role of BCS1L in RISP (UQCRFS1) assembly into CIII. (A) A schematic simplification 
of RISP mitochondrial import, assembly into CIII, and processing. (B) Three domains of human 
BCS1L. GRACILE syndrome mutation is located at amino acid residue 78 (p.S78G). AAA, ATPases 
associated with various cellular activities.
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A large proportion of CIII dimers physically connect to CI and or CIV to form large 
structural entities called supercomplexes.57,58 The composition and stoichiometry of 
supercomplexes vary in a cell type-specific manner. In addition, new evidence suggests 
the existence of supercomplexes in which mitochondrial fatty acid oxidation enzymes 
trifunctional protein and ETFDH physically interact with CI and CIII, respectively.59 The 
physiological significance of supercomplexes is under debate.57,58 The supercomplexes may 
compartmentalize the coenzyme Q and cytochrome c between their respective reaction 
centers with a kinetic advantage and attenuation of harmful side reactions leading to 
superoxide production. However, almost an equal amount of evidence for and against this 
theory exits.58 It remains possible that the supercomplex formation is solely an inevitable 
consequence of the high protein density in the inner mitochondrial membrane and a 
solution to prevent protein aggregation.  
6.2.3 Superoxide production by CIII
CIII is one of the mitochondrial sources of superoxide, an oxygen radical and a precursor for 
other reactive oxygen species (ROS).60 CIII can uniquely emit superoxide to both sides of the 
mitochondrial inner membrane: into matrix and inner-membrane space. The superoxide 
in the inner-membrane space enzymatically or spontaneously dismutates to hydrogen 
peroxide, which can take part in cellular signaling as it can reach the cytoplasm. The 
superoxide production takes place at the Qo site and derives from the unstable semiquinone 
intermediate.61 Mutations and inhibitors that affect the catalytic function of CIII may either 
increase or decrease the superoxide production.62 Typically, inhibitors (e.g. antimycin A) or 
mutations that block the Qi site enhance the superoxide production. In contrast, inhibitors 
(e.g. stigmatellin or myxothiazol) or mutations that inhibit the quinol oxidation decrease 
or completely block the superoxide production. Mitochondrial membrane potential has 
also a profound effect on the superoxide production by CIII.63 In fact, isolated native CIII 
or other cytochrome bc1 complexes do not produce a measurable amount of superoxide in 
the absence of membrane potential unless the enzyme is inhibited by antimycin A.63,64 CIII 
is also an important determinant of superoxide production elsewhere in the respiratory 
electron transfer, as it modulates the redox status of the coenzyme Q pool. Over-reduced 
coenzyme Q pool may lead to reverse-electron flow reactions, most notably at the level of 
CI.65 
6.3 Mitochondrial diseases
Mitochondrial diseases are a clinically and genetically diverse group of in-born errors of 
metabolism caused by mutations in nuclear DNA and mtDNA.9 Their estimated collective 
prevalence is one per 5000 births.10 A mitochondrial disease may present as myopathy, 
cardiomyopathy, hepatopathy, kidney disease, neurological disorder, endocrine and 
hematological disturbance, or with other symptoms in isolation or in various combinations 
with onset at any age.9 The inheritance of mitochondrial diseases caused by nuclear DNA 
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mutations follows the Mendelian rules. In contrast, mtDNA is maternally inherited. Because 
mtDNA is a multicopy genome, mtDNA mutations can be homoplasmic or heteroplasmic. 
In heteroplasmy, both wild-type and mutated mtDNA exist in different proportions. The 
degree of heteroplasmy may vary between different tissues and cell types. The inheritance 
of mtDNA mutation load is unpredictable due to a bottle-neck phenomenon in mtDNA 
amount during female germline development.66 
6.3.1 CIII deficiencies
CIII deficiencies are relatively rare mitochondrial diseases.13 Over 40 mutations have been 
found in MT-CYB and over 20 mutations in BCS1L. Mutations in other CIII-related genes, 
mainly encoding auxiliary subunits (UQCRB67, UQRCQ68 and UQCRC269) or assembly 
factors (LYRM770, UQCC271, UQCC372, TTC1973), are limited to a few cases.  Excluding the 
patients with mutations in MT-CYB, only four patients have been reported with mutations 
in the two other catalytic subunits: in RISP74 and in cytochrome c1 (CYC1)75. Symptoms in 
CIII deficiencies are diverse, as typical of mitochondrial diseases, and range from exercise 
intolerance76 to severe neurological manifestations68, and early-onset lethal metabolic 
crises15. Even mutations in the same gene and affecting the same part of the protein can 
cause vastly different phenotypes.77
6.3.2 MT-CYB mutations and polymorphisms
The MT-CYB protein has its highly conserved regions preserved in bacteria, plants, and 
animals but, overall, it is also highly polymorphic.13 In fact, forensic researchers commonly 
utilize the MT-CYB nucleotide sequence for species identification.78 In humans, more than 
450 missense changes exist in MT-CYB according to the Human Mitochondrial Genome 
Database (mitomap.org79). Not surprisingly, MT-CYB mutations were the first identified 
causes of CIII deficiency.76,80,81 The majority of the identified MT-CYB mutations are sporadic 
and heteroplasmic, with typically high mutation load in skeletal muscle.13 Frequently, MT-
CYB mutations manifest as exercise intolerance and progressive myopathy,13,76 sometimes as 
cardiomyopathy82. In contrast to nuclear mutations affecting CIII, which typically manifest 
soon after birth, MT-CYB mutation-related pathology commonly emerges at childhood 
or adulthood.13 In some patients, central nervous system manifestations accompany the 
myopathic features.83–85 Only one verified case of CIII deficiency has been homoplasmic 
for a MT-CYB mutation.86 This mutation led to a neonatal-lethal multisystemic disease. 
In addition, MT-CYB mutations and variants appear to contribute to Leber Hereditary 
Optic Neuropathy (LHON) caused by mutations in mtDNA-encoded CI subunits.13 A 
homoplasmic MT-CYB variant has also presumably exacerbated a CIII deficiency with 
unidentified nuclear origin.87 
The characterization of MT-CYB mutations have proven challenging due to the lack of 
technology to introduce targeted mutations into the mammalian mtDNA. Therefore, 
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biochemical studies have relied on yeast88 and bacterial models89, where MT-CYB homologs 
are amenable to genetic manipulation, or transmitochondrial cybrid cells87. Interestingly, 
some non-pathogenic human MT-CYB variants studied in yeast have shown a rather 
profound effect on CIII function despite the non-pathogenic nature.90 Moreover, some 
MT-CYB variants possibly alter pharmacological responses to drugs with affinity for Qo site 
of CIII such as the anti-malarial drug atovaquone and the antidepressant clomipramine.90
6.3.3 BCS1L mutations and GRACILE syndrome
BCS1L mutations are the most common diagnosed cause of CIII deficiency.91 All identified 
BCS1L mutations are recessive and spread across the three domains of the protein with 
no clear genotype-phenotype correlation (Fig.4B).77 However, the recently published 
crystal and cryo-electron microscopy structures of BCS1L may bring new insights into the 
phenotypic variability among the BCS1L mutations.51,52 The symptoms in BCS1L-related 
pathologies range from Björnstad syndrome77 with sensorineuronal hearing loss and 
aberrant hair phenotype to lethal metabolic crises of neonates.91 A common onset is at fetal 
period or soon after birth. Excluding the Björnstad syndrome, BCS1L mutations typically 
present as a failure to thrive with liver and kidney involvement, and lactic acidosis. However, 
some patients have shown central nervous system manifestations without obvious visceral 
phenotype.92,93 In contrast to MT-CYB mutations, myopathy is an infrequent presentation 
of BCS1L mutations.
GRACILE syndrome is the most severe disease caused by BCS1L mutations.16,94 It is also 
the most thoroughly characterized CIII deficiency (>40 patients). All the patients have 
had Finnish ancestry. The name of the syndrome derives from the main clinical features: 
growth restriction, aminoaciduria, cholestasis, iron overload in the liver, lactic acidosis, 
and early lethality. The growth restriction starts already during the fetal period and the 
patients are born small for the gestational age (-4 SD) and lack subcutaneous adipose 
tissue.16,17,95 Clinical chemistry analyses show increased lactate concentration in the blood, 
and loss of amino acids, glucose and lactate into the urine. Typical histological findings are 
accumulation of bile acids, iron, and lipids in the liver. The iron accumulation is specific 
to liver and not present in other organs. The renal histology shows decreased number of 
proximal tubules with morphological alterations. The lifespan of the patients is from few 
days to few months. During the short lifespan, the patients do not show obvious central 
nervous system manifestations, although a few patients have shown atypical responses 
to sound stimulus, suggestive of Björnstad syndrome-type sensorineural hearing loss. 
All GRACILE syndrome patients have had the same Finnish founder mutation c.A232G 
(p.S78G). Outside Finland, other BCS1L mutations have caused GRACILE-like syndromes, 
however, without the full clinical picture of the GRACILE syndrome.90,96,97
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6.4 Liver, the center of metabolism
6.4.1 Liver anatomy and physiology
Liver is the largest visceral organ.98,99 It is located in the right upper abdominal cavity 
beneath the diaphragm. The lobes of the liver connect to hepatic artery, biliary tract, and 
portal vein. The portal vein brings low-oxygen nutrient-rich blood from the gastrointestinal 
tract to the liver. In contrast, the hepatic artery delivers oxygen-rich blood for the liver. 
Most water-soluble nutrients, xenobiotics and drugs undergo hepatic filtration before 
reaching other tissues. The biliary tract delivers bile acids to aid solubilization of dietary 
lipids in the small intestine. 
The functional unit of liver is a liver lobule comprising a branch of the central vein 
surrounded by liver parenchyma, and multiple portal areas (Fig. 5).98,99 Each portal area 
has three components: a branch of portal vein, arteriole(s), and bile duct(s). The direction 
of blood is towards the central vein through sinusoidal capillaries while the bile flows 
the opposite direction in the bile ductules. Microscopically, the liver appears relatively 
homogenous. However, a deep metabolite and oxygen gradient exist across the liver 
parenchyma.100 Likewise, hepatocyte functions are regionally compartmentalized. For 
example, after feeding, the periportal hepatocytes conduct gluconeogenesis while the 










Figure 5. A cross-section of liver lobule stained with hematoxylin and eosin. CV, central vein; 
PV, portal venule. The direction of blood and bile are shown. Yellow arrow heads point to bile 
ducts and hepatic arterioles (small duct-like structures) next to PV.
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Other abundant cells in the liver are cholangiocytes (bile duct epithelial cells), Kupffer cells 
(resident macrophages), stellate cells and sinusoidal endothelial cells.
Liver is undeniably the center of organismal metabolism.98 It produces most of the circulating 
proteins in the blood such as albumin, transferrin, and lipoproteins. Approximately 40% 
of hepatic mRNA encode secreted proteins.101 In addition, liver releases biosynthetic 
precursors such as cholesterol for other tissues. 98 Liver is also the main site of glycogen 
storage. Importantly, the hepatic glycogen is available for release into the circulation and 
serves as an important buffer for blood glucose. During fasting the hepatic glycogenolysis 
and gluconeogenesis become the main source of blood glucose. Liver also stores iron, 
copper, and vitamin A. Many vital detoxification processes including the urea cycle and 
the detoxification of xenobiotics takes place in the liver. Moreover, liver is an endocrine 
organ.102 It secretes insulin-like growth factor and numerous hepatokines including 
stress-inducible hormones such as FGF21. In essence, liver is an organ that supports the 
maintenance of homeostasis in every tissue of the body.
6.4.2 Hepatic manifestations in OXPHOS disorders
An estimated 20% of neonatal OXPHOS defects manifest as hepatopathy.103 Adult-
onset mitochondrial hepatopathies are rare. Typical hepatic manifestations are steatosis, 
cholestasis, glycogen depletion, and hypoglycemia with lactic acidosis. Iron accumulation 
in hepatocytes and Kupffer cells is a hallmark of GRACILE syndrome but also present in 
some mtDNA depletion syndromes.103–105 Hepatopathies related to isolated CI deficiency 
are virtually nonexistent in the literature. Hepatopathies due to isolated CIV deficiency 
are also rare and generally limited to the mutations in SCO1 involved in copper transfer 
to CIV.106 The two major classes of mitochondrial hepatopathies are mtDNA depletion 
syndromes, and CIII deficiencies due to mutations in nuclear DNA-encoded subunits 
and assembly factors.103 It remains unclear why these particular OXPHOS defects cause 
hepatopathy. According to animal models, insufficient mitochondrial ATP production 
or fatty acid oxidation appear not to be the sole factors. In mouse liver, disruption of 
mitochondrial fatty acid oxidation107, membrane potential108 or ADP/ATP exchange109 does 
not cause overt liver damage under unstressed conditions.  
6.5 Mouse models of CIII deficiency
A very limited repertoire of animal models exists for CIII deficiency. Full knock out of 
any subunit of CIII is likely embryonically lethal. Cell-type specific RISP and UQCRQ 
knock-out cells and mice have been utilized to investigate the role of respiratory electron 
transfer and CIII in cell differentiation110, angiogenesis111, hypoxia signaling112 and adaptive 
immunity113. Mice carrying an artificial heterozygous RISP p.P224S mutation have been 
used to study aging but only minor sex-specific phenotypes were found.114 Whole-body 
knock-out mice of TTC1955 or PARL115, needed for proteolytic processing of TTC19, are 
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viable, cause a mild CIII deficiency, and to some degree phenocopy the central nervous 
system manifestations of TTC19 mutations in patients. The only patient mutation animal 
model of CIII deficiency is the Bcs1lp.S78G knock-in mouse carrying the GRACILE mutation.18
6.5.1 Bcs1lp.S78G knock-in mouse model of GRACILE syndrome
The Bcs1lp.S78G mutant mice carry the same missense mutation as the GRACILE syndrome 
patients.18 Unlike the patients, the Bcs1l mutant mice are born healthy but soon after 
weaning fail to grow and developed lactic acidosis, hypoglycemia, and liver and kidney 
disease. The CIII activity and the amount of fully assembled CIII are grossly normal at 
birth but gradually diminish coinciding with the appearance of the disease manifestations. 
Histologically the most affected organs are liver and kidney. The liver histology of the 
mutants shows periportal degenerating hepatocytes, glycogen depletion, and progressing 
fibrosis. The hepatic iron accumulation is less prominent than in the patients. The kidney 
histology shows decreased tubular mass and luminal casts suggestive of proteinuria. The 
lifespan of Bcs1lp.S78G mice ranges from 28 to 38 days on a Lund University C57BL/6JBomTac-
derived background.18,116,117 
6.6 Overview of strategies to improve dysfunctional mitochondria
Generally, there is no cure for mitochondrial diseases.118,119 In a few special cases, a 
supplement can bypass the underlying defect such as in mitochondrial depletion syndrome 
due to thymidylate kinase 2 deficiency.120 Gene therapy may be the only effective treatment 
for many mitochondrial diseases. However, many recent advances in the gene therapy 
field are valid only for the correction of nuclear DNA mutations. Targeting the multicopy 
mitochondrial genome is more challenging and the suggested tools are still in the very 
early stages of development.118 
Preclinical interventions in animal models have given some hope that it may be possible to 
improve mitochondrial function in mitochondrial diseases.118,119 One proposed approach 
is to increase mitochondrial biogenesis to compensate the dysfunctional mitochondria. 
Increased mitochondrial number is a frequent phenotype in some mitochondrial defects 
suggestive of an endogenous compensatory response.104,121,122 Aberrant mitochondrial 
accumulation seen as ragged-red fibers is also a hallmark of mitochondrial myopathies.123 
Nevertheless, many mitochondrial diseases do not show increased mitochondrial biogenesis 
and may thus benefit from exogenous stimulation. Usually the strategies to increase 
mitochondrial biogenesis target metabolic regulators such as AMPK, sirtuin 1 (SIRT1), 
PPARα (peroxisome proliferator-activated receptor alpha) and PGC-1α (peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha), which mediate adaptive 
mitochondrial responses.118,119,124 Initially, PGC-1α overexpression-mediated increase in 
mitochondrial biogenesis proved beneficial in mouse models of CIV assembly defects.125 
PGC-1α is a master regulator of mitochondrial biogenesis.124,126 It serves as a transcriptional 
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coregulator in induction of gene expression leading to enhanced oxidative metabolism in 
tissue- and isoform-specific manner.
Pharmacological PGC-1α activation strategies target AMPK and SIRT1 which activate 
it by phosphorylation and deacetylation, respectively.118,119 AICAR (5-aminoimidazole-
4-carboxamide ribonucleotide ), an AMPK activator, has attenuated myopathy in four 
mouse models of CIV deficiency.125,127 Cellular nicotinamide adenine dinucleotide (NAD+) 
concentrations regulate SIRT1 deacetylase activity.128 Inhibition of NAD+ consuming 
processes (poly-ADP-ribose polymerases) or administration of NAD+ precursors have 
also proven highly promising ways to attenuate secondary or primary mitochondrial 
dysfunction (section 6.8.3).129–131 PGC-1α is a transcriptional coactivator for PPAR 
transcription factors.132,133 The promoter of PPARGC1A gene encoding PGC-1α also 
contains a PPAR response element by which PGC-1α can upregulate its own expression. 
Therefore, PPAR agonists were thought to be efficient inducers of mitochondria biogenesis, 
and, indeed, a pan-PPAR agonist bezafibrate induces mitochondrial biogenesis in patient 
fibroblasts with different OXPHOS defects.134  However, in mouse models of mitochondrial 
diseases, bezafibrate has mainly up-regulated fatty acid oxidation-related gene expression 
with both harmful and beneficial outcomes.125,135,136 Nevertheless, an uncontrolled clinical 
trial on bezafibrate in mitochondrial myopathy was launched and its recent results suggest 
that the therapeutic effects are relatively modest.137 At least four other clinical trials with 
mitochondrial biogenesis as a biochemical outcome parameter are also in progress.118  
In contrast to SIRT1-AMPK-PGC-1α-axis activation, mtTOR pathway activation stimulates 
anabolic reactions.138 The mtTORC1 inhibitor rapamycin has shown beneficial effects in 
several mouse models of mitochondrial diseases,139–142 but it did not benefit mice with a 
coenzyme Q deficiency143. The exact mechanism of the beneficial effect is not yet clear, 
but induction of autophagy and clearance of dysfunctional mitochondria is one proposed 
mechanism.140,141 Correction of aberrant mtTORC1 signaling in a mitochondrial myopathy 




Ketosis is a physiological adaptation to prolonged starvation or lack of dietary 
carbohydrates.144 A separate type of ketosis is the pathological ketoacidosis in diabetes.145 
In ketosis, repressed glucose utilization and increased fatty acid oxidation forces the 
liver to produce ketone bodies for those cells that cannot utilize fatty acids as an energy 
source.144 β-hydroxybutyrate and acetoacetate are the relevant circulating ketone bodies, 
and they derive from the acetyl-CoA of fatty acid oxidation. The function of ketosis is to 
limit wasting of tissue protein for gluconeogenesis. Human brain can adapt to replace 
approximately 50% of glucose utilization with ketone bodies.146 Gluconeogenesis in liver 
and to some degree in kidneys supply the residual glucose need.147 
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6.7.2 Composition of ketogenic diets
The classical ketogenic diet provides ~90% of energy as fat, sufficient amount of protein 
(typically 1 g / kg body weight), and minimal amount of carbohydrates.144 In addition, 
several variations exist. Most of them are modified Atkins-type diets that have higher 
protein content than the classical ketogenic diet. Some ketogenic diet formulations contain 
high proportion of medium-chain triglycerides, which allows attenuation of carbohydrate 
restriction without the loss of ketogenesis.148 
Commercial ketogenic rodent chows are also available for research purposes. The 
achievement of dietary ketosis in rodents requires strict restriction of not only carbohydrates 
but also protein.149 The protein restriction has proven problematic in some cases, and one 
widely used commercial ketogenic chow causes hepatotoxicity and weight loss linked to 
overt choline and methionine deficiency.150,151 This problem is rarely discussed and many 
studies do not report adequately the composition or commercial source of the chow to allow 
evaluation of whether the noted effects are due to nutritional ketosis or malnutrition. As an 
example, some studies have attributed over 40-fold upregulation of hepatic Fgf21 expression 
as an effect of ketogenic diet,152 when in fact the same diet supplemented with methionine 
induces Fgf21 expression only minimally.151 FGF21 is a marker for mitochondrial diseases 
but also an important endocrine regulator in fasting and feeding responses in normal 
physiology.153 Another potentially relevant parameter in ketogenic diets is the fat source. 
Dietary fatty acid composition affects the mitochondrial phospholipid acyl chain profile, 
including that of cardiolipin to some degree.154,155 Moreover, some metabolites of the 
unsaturated fatty acid metabolism are ligands for PPAR transcription factors.156 
6.7.3 Ketogenic diet as a therapy for mitochondrial disease
The regulation of mitochondrial biogenesis, dynamics and function are inherently linked 
to starvation signals that aim to enhance OXPHOS efficacy during energy scarcity.21,157 
Accordingly, fasting and caloric restriction can cause beneficial mitochondrial changes in 
animal models and humans.158–160 Ketogenic diet has a long history as a mimetic of anti-
epileptic starvation ketosis in the management of epilepsy.161 The mechanism of action 
of ketogenic diet in epilepsies is unknown but involvement of an adaptive mitochondrial 
response has been proposed.162 In mitochondrial diseases, ketogenic diets may also relieve 
dependence on anaerobic glycolysis by forcing the cells to oxidize fatty acids and ketone 
bodies.162,163
The first demonstration of the beneficial effect of ketone bodies in mitochondrial dysfunction 
came from cybrid cells with mtDNA deletions in which ketone body supplemented-media 
shifted heteroplasmy towards wild-type mtDNA.164 The authors of this study presented 
evidence suggesting intracellular selection for wild-type mtDNA upon ketone body 
treatment. An independent study has confirmed the attenuation of mtDNA mutation load 
in patient cell lines.165 In a neuronal cell line carrying essentially homoplasmic MELAS 
(mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) mutation, 
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ketone bodies increased mtDNA amount and restored CI assembly defect.166  In contrast, 
in a mouse model of myopathy with progressive accumulation of mtDNA deletions due 
to mutated mitochondrial TWINKLE helicase, ketogenic diet did not affect mtDNA 
mutation load or amount.167 However, ketogenic diet decreased the number of cytochrome 
oxidase-negative muscle fibers, normalized mitochondrial structural aberrations, and 
increased mitochondrial mass according to citrate synthase activity. In a mouse model 
of mitochondrial translation deficiency, ketogenic diet has also ameliorated OXPHOS 
defects, especially in the liver.168 Correction of mtTOR pathway hyperactivity and increase 
in AMPK signaling accompanied the beneficial effect. A rather different outcome took 
place in a mouse model of mtDNA depletion syndrome (MPV17-/-) in which ketogenic 
diet caused liver failure.55 However, this report did not disclose the chow composition or 
source and therefore it remains unclear whether the diet caused a choline and methionine 
deficiency.
Clinical trials on ketogenic diet in mitochondrial diseases are scarce. Ketogenic diet is an 
approved therapy for drug-resistant epilepsy169, pyruvate dehydrogenase170 and glucose 
transporter 1171 deficiencies. A retrospective uncontrolled cohort study also suggests 
ketogenic diet as an efficient and relatively safe therapy for epilepsies caused by primary 
OXPHOS defects.172 In mitochondrial myopathy patients (primary or secondary mtDNA 
deletions), ketogenic diet caused acute muscle pain that lead to premature discontinuation 
of the intervention.173. However, the cell lysis behind the muscle pain appeared to be selective 
for ragged-red fibers, muscle fibers with the accumulation of aberrant mitochondria. A 
single case report described a partial recovery of alopecia with unaffected progression of 
sensorineuronal hearing loss in CIII deficiency (Björnstad syndrome) on ketogenic diet.174 
In addition to putative starvation-like adaptive response targeting mitochondria, ketogenic 
diet may also have other mechanisms of action. Ketone bodies have themselves endogenous 
signaling functions. The main circulating ketone body β-hydroxybutyrate inhibits NRLP3 
inflammasome activation175 and is an endogenous ligand for the niacin receptor HCAR2 
(GPR109A)176. β-hydroxybutyrate is also a proposed histone deacetylase inhibitor,177 
although not all studies agree.178 The signaling functions of β-hydroxybutyrate in the 
context of mitochondrial dysfunction, however, remain unstudied. 
     
6.8 Targeting NAD+ metabolism in mitochondrial dysfunction
6.8.1 NAD+ in cellular metabolism and signaling
Nicotinamide adenine dinucleotide (NAD+) is a ubiquitous vital cellular electron-carrying 
coenzyme of oxidative metabolism.128 OXPHOS, or lactate production and excretion, 
maintains its reduced form (NADH) at low concentration The reduction-oxidation 
reactions of oxidative metabolism recycle the NAD+/NADH pair but do not consume the 
NAD+ molecule. The processes that consume NAD+ are not directly involved in energy 
metabolism but in cellular signaling, protein posttranslational modification, and DNA 
damage response.128 In addition, NAD+ is a precursor for the biosynthesis of NADPH 
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(reduced nicotinamide adenine dinucleotide phosphate), an important source of reducing 
equivalents required for biosynthetic reactions and maintenance of cellular antioxidant 
systems. Four known NAD+ consuming enzyme families exist in mammals: sirtuins (SIRT1-
SIRT7)179, ADP-ribose transferases and polymerases (PARP1- PARP17)180, CD38 and 
CD157 NAD+ hydrolases181, and SARM1 NAD+ hydrolase182. The sirtuin family members 
SIRT1 and SIRT3 are especially important in the regulation of mitochondrial function.128 
They serve as NAD+-dependent lysine deacetylases and NAD+ concentration is likely rate 
limiting for their activity based on Michaelis-Menten constant for NAD+. SIRT1 localizes 
predominantly to nucleus and deacetylates a number of lysine residues in transcriptional 
regulators including in PGC-1α.128,183 SIRT3 is a mitochondrial deacetylase with numerous 
substrates including several respiratory complex subunits.179 In contrast to enzymatic 
protein acetylation in the nucleus and cytoplasm, protein acetylation in mitochondrial 
matrix is a constant nonenzymatic process due to high pH and high concentration of 
acetyl-CoA.184,185 
6.8.2 NAD+ biosynthesis
The vitamin B3s nicotinic acid (niacin) and nicotinamide are the classical NAD+ precursors.128 
Nicotinamide is also the product of all NAD+ consuming processes and salvageable to 
NAD+ in most cells. Nicotinamide is two enzymatic steps away from NAD+ (Fig. 6). The 
rate-limiting enzyme in the NAD+ salvage is nicotinamide phosphoribosyltransferase 
(NAMPT), which inhibition186 or overexpression187 alters cellular NAD+ concentrations. 
Endogenously, NAMPT is under transcriptional regulation by clock genes and SIRT1, 
giving circadian rhythm to cellular NAD+ levels.188,189 
Gut microbiota affects NAD+ metabolism by metabolizing a large proportion of dietary 
nicotinamide to nicotinic acid.190 Both of these NAD+ precursors are highly bioavailable, 
but different pathways conduct their conversion to NAD+ in tissue-specific manner 
(Fig. 6).191,192 The Preiss-Handler pathway enzymes, mainly in gut epithelia, liver and 
kidney,  metabolize nicotinic acid to NAD+, which will eventually undergo conversion to 
nicotinamide (Fig. 6). By contrast, nicotinamide is the main circulating NAD+ precursor 
and the main substrate for NAD+ biosynthesis in most tissues including skeletal muscle, 
heart, adipose tissue and central nervous system.191,192 In addition, some tissues, primarily 
liver and kidney, can synthetize the pyridine ring of NAD+ de novo from tryptophan for the 
biosynthesis of nicotinic acid mononucleotide which joins the Preiss-Handler pathway in 
the NAD+ biosynthesis.192 Liver plays an important role in whole body NAD+ metabolism 
by releasing nicotinamide for NAD+ biosynthesis in extrahepatic tissues.
A reinvestigation of NAD+ biosynthetic routes in 2004 led to a discovery of a novel vitamin 
B3, nicotinamide riboside (NR).193 NR has some potential advantages over nicotinic acid 
and nicotinamide when the aim is to increase cellular NAD+. First, large doses of nicotinic 
acid cause cutaneous vasodilation observed as redness and heat due to stimulation of 
HCAR2 receptor.194 NR and nicotinamide do not stimulate HCAR2.129 Second, NR, being 


































Figure 6. NAD+ biosynthetic pathways. Molecules referred with red text indicate NAD+ 
precursors that can be administered to increase NAD+ biosynthesis. The enzymes involved 
are marked next to the arrows using their official gene symbols. The enzymes that can be 
pharmacologically targeted are marked with blue-colored text. NR, nicotinamide riboside.
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is also under positive feedback inhibition by NAD+.193,195 Third, nicotinamide is a product 
of NAD+ consuming reactions and serves as negative feedback inhibitor for sirtuins.196 
However, recent NAD+ metabolite flux analyses have shown that enterohepatic metabolism 
converts almost all orally administered NR to nicotinamide.190,192 Moreover, NR degrades 
to nicotinamide within minutes in whole blood.192,197 The same is true for intravenously 
administered phosphorylated NR (nicotinamide mononucleotide, NMN).192 Interestingly, 
the reduction of NR to dihydro-NR (NRH) slows down the cleavage to nicotinamide, 
which renders NRH a more potent enhancer of cellular NAD+ levels in culture and in vivo 
than NR.197–199 However, NRH is still a very recent innovation as a NAD+ precursor and 
little studied.    
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6.8.3 NAD+-repletion therapies
Vitamin B3 and tryptophan deficiency causes pellagra, a potentially lethal condition 
characterized by photosensitive dermatitis, diarrhea, and dementia.200 Relatively recently, 
a secondary NAD+ depletion not related to malnutrition or malabsorption has been found 
in animal models of different metabolic conditions.201–205 Usually, NAD+ depletion involves 
a repression of mitochondrial respiratory activity. The aim of NAD+-repletion therapies is 
to normalize cellular NAD+ concentration and typically enhance mitochondrial function 
by targeting the NAD+-dependent metabolic regulators SIRT1 and SIRT3.128 The cellular 
NAD+ concentration can be increased by promoting its biosynthesis or by decreasing its 
consumption (Fig. 6). 
The preclinical interventions have mainly utilized the novel NAD+ precursors NR and NMN 
to promote NAD+ biosynthesis.129–131,201,203,204,206,207 However, rarely have the studies included 
a side-by-side comparison to nicotinic acid or nicotinamide. Two experimental drugs also 
exist to target key enzymes in NAD+ biosynthesis. Inhibition of ACMSD, an enzyme that 
channels a vital intermediate of tryptophan catabolism away from NAD+ biosynthesis, 
normalized hepatic NAD+ levels in mice fed methionine- and choline-deficient diet.205 
A small-molecule NAMPT activator also exists but its effects in disease models are still 
unreported in the literature.195 An alternative approach to increase cellular NAD+ levels 
is to inhibit the NAD+ consuming processes, mainly PARP1 and CD38. Inhibition of 
either of the enzymes in mice shows increased cellular NAD+, enhanced activity of SIRT1 
and OXPHOS.181,203,208 However, the importance of PARP1 in DNA repair likely limits 
the usability of its inhibitor in humans. CD38 has immunomodulatory functions and its 
pharmacological inhibition are unstudied in disease models.
By now, the so-called NAD+-boosting therapies have been studied in more than 30 
rodent disease models with mostly beneficial outcomes.128 However, the first randomized 
controlled clinical trials on NR in insulin-resistant obese209, and in elderly men210, have not 
shown prominent effects on skeletal muscle mitochondrial function or NAD+ levels. In two 
mouse models of mitochondrial myopathy, NAD+-based therapy ameliorated the disease. 
Cerutti et al. showed that PARP1 inhibition or NR supplementation for 4 weeks increases 
skeletal muscle respiratory enzyme activities and improves exercise tolerance in mice 
with mutated CIV assembly factor SCO1.130 They also found that NR increased NAD+-
to-NADH ratio in skeletal muscle while mtDNA content and citrate synthase activity, 
markers of mitochondrial mass, remained unchanged. Khan et al. investigated a longer, 
16-week, NR treatment on a late-onset mitochondrial myopathy model with progressive 
mtDNA deletions.131 They found attenuation of multiple hallmark phenotypes of the 
model: decreased mtDNA mutation load and number of cytochrome c oxidase-negative 
muscle fibres, and increased mitochondrial cristae density.  Whether NR increased the 
NAD+ levels in this model remains unclear but increased citrate synthase activity and 
respiratory enzyme proteins suggested increased mitochondrial mass due to the NR 
supplementation. In CI-deficient mice (Ndufs4 knockout), intraperitoneally administered 
NMN has extended the survival of the knockout mice. In this model, NMN administration 































Figure 7. Alternative oxidase (AOX) in respiratory-electron transfer. (A) In uncompromised 
respiratory-electron transfer, CIII outcompetes AOX in ubiquinol (QH2) oxidation. (B) Upon CIII-
CIV segment insufficiency, AOX oxidizes ubiquinol and reduces oxygen to water bypassing CIII 
and CIV.
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mice.  The beneficial effects in myopathic mice provided a basis for an uncontrolled clinical 
trial on nicotinic acid supplementation in mitochondrial myopathy patients.211 The patients 
showed low baseline whole blood and skeletal muscle NAD+ levels that were improved after 
4 and 10 months of supplementation. At the end of the follow-up mtDNA amount and 
mutation load, and structural aberrations of mitochondria were similar to the baseline. 
However, the number of cytochrome c oxidase-negative muscle fibers had decreased, 
suggesting improved OXPHOS. 
 6.9 Xenogenic alternative oxidase expression in mammalian cells, 
and mice
Mammalian mitochondria have only one quinol oxidase (CIII) and only one terminal 
oxidase (CIV). Some lower animals, plants and fungi, however, have alternative oxidases 
(AOXs) that can bypass the CIII-CIV segment of respiratory electron transfer (Fig. 7).212 
In these organisms, AOXs are mostly not constitutively active but take over the respiration 
under specific conditions that likely involve an accumulation of reduced coenzyme Q.212,213 
In addition, some blood-borne parasites such as Trypanosoma brucei, causative for sleeping 
sickness, utilize AOX to speed-up aerobic glycolysis.214 As AOX bypasses two out of three 
proton translocases (CIII and CIV) in the OXPHOS, respiring on AOX is a relatively 
inefficient way of generating ATP.
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Transgenic AOXs from the tunicate Ciona intestinalis and the fungi Emericella nidulans have 
been studied in several mammalian cell lines27,215–217 and also in mice218,219. These enzymes 
correctly localize to mammalian mitochondrial inner-membrane and restore respiration 
upon the blockade of the CIII-CIV segment of the electron transfer. With uncompromised 
CIII and CIV AOXs remain largely inert.218,219 Healthy mice expressing AOX show no 
obvious phenotype except the expected resistance to CIII and CIV inhibitors.218,219 AOXs 
have proven useful mechanistic tool to study the role of different segments of the respiratory 
electron transfer for example in mitochondrial ROS production65. In mtDNA depleted 
cells, AOX can restore uridine auxotrophy by allowing the enzymatic activity of coenzyme 
Q-dependent DHODH.27,220 Under certain circumstances, AOXs can also alter hypoxia 
responses221, and prevent succinate accumulation-related ROS signalling222. 
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7 AIMS OF THE STUDY
The aim of this thesis was to elucidate disease mechanisms in CIII-deficiency by means 
of dietary, pharmacological, and genetic interventions, with an emphasis on relevance to 
therapy development. The main organ of interest was the liver. The fourth study arose from 
an unexpected identification of a novel mouse mtDNA variant. The specific aims were:
1) To study the effect of ketogenic diet on mitochondrial hepatopathy in Bcs1lp.S78G mice.
2) To characterize NAD+ metabolism and signaling, and the effect of NAD+-precursor 
therapy in Bcs1lp.S78G mice
3) To study AOX-mediated restoration of electron transfer upstream of CIII in Bcs1lp.S78G 
mice.
4) To characterize the effect of mt-Cybp.D254N variant on Bcs1l wild-type and mutant mice.
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8 METHODS
The original publications describe the methods (Table 1) in detail. Here, the design of the 
studies and the animal experiments are summarized. 
8.1 Mouse strains and ethics
We studied the Bcs1lp.S78G knock-in mice18 on two different congenic backgrounds. In 
University of Helsinki, the mice were on C57BL/6JCrl (Study, I, II, III, IV) and in Lund 
University on a local C57BL/6JBomTac-derived background (II). In study IV, we also 
generated F1 hybrid mice from these two substrains. Both female and male mice were used 
in the experiments.  
The Animal Experiment Board, Finland (ELLA) authorized the animal experiments in 
Helsinki under the permits: ESAVI-2010-07284/Ym-23, ESAVI/6142/04.10.07/2014 and 
ESAVI/6365/04.10.07/2017.  The experiments in Sweden were performed under the Lund 
University/M124-15 licence. All animal experiments and reporting were carried out in 
accordance to the FELASA (Federation of Laboratory Animal Science Associations) and 
ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines.
8.2 Monitoring of condition of Bcs1lp.S78G homozygotes
We used a semi-quantitative scoring system116 based on behavioral changes and weight loss 
to minimize the suffering of the mice, and to prevent spontaneous deaths, and to estimate 
survival. The behavioral scoring comprises six parameters: waddling gait, reduced curiosity, 
lack of movement, kyphosis, loss of balance, and loss of grip strength. Each parameter was 
scored on a 3-point scale (0, normal; 1, moderate; 2 severe). If the mice reached a total score 
higher than 7 or weight loss more than 20%, they were euthanized. For survival analyses, 
the personnel performing the scoring were unaware of any group allocations. 
8.3 Ketogenic diet intervention
The control mice received a cereal and soy-based rodent chow (Teklad 2018, Harlan). Its 
macronutrient energy composition (% of energy, E%) was 18 E% fat, 58 E% carbohydrates, 
and 24 E% protein. The ketogenic chow was based on vegetable oils (soybean, palm and 
corn oil) and casein. It provided 90.5 E% fat, and 9.1 E% protein. The fatty acid profile of 
the chow was following: 21 E% saturated fatty acids, 35 E% monounsaturated fatty acids, 
30 E% linoleic acid, and 2.5 E% linolenic acid. Both chows contained standard vitamin 
and mineral supplements and provided similar amount of choline (~8.5 mg/100kJ) and 
methionine (~30 mg/100kJ). All mice were familiarized to the ketogenic chow in the 
presence of standard chow before weaning. After weaning (3 weeks of age), the litters 
received ad libitum control or ketogenic chow only. One experimental set of mice was 
35
euthanized after 3 weeks (n=11-14/group). A second interventions lasted for 10 weeks 
(n=8-9/group).
8.4 NR supplementation
Randomized Bcs1lp.S78G homozygotes and their heterozygous or wild-type littermates 
received either control chow (Teklad 2018, Harlan) or the same chow supplemented 
with NR (2.4 g/kg chow) starting at weaning. The estimated NR dosage was 400 mg/
kg body weight. Novalix Pharma (Strasbourg, France) custom synthetized the NR as 
a trifluoromethanesulfonate (triflate) salt. Several previous studies have used the same 
NR formulation.129,130,201 The mice were followed for 3 months in Helsinki (C57BL/6JCrl 
background) (n=8/group) and until the development of terminal stage in Lund University 
(C57BL/6JBomTac-derived background) (n=5-6/group).
8.5 AOX-expressing mice
We crossbred Ciona intestinalis AOX transgenic mice219 with Bcs1lp.S78G heterozygotes 
to obtain suitable breeding mice to produce Bcs1lp.S78G homozygotes with and without 
heterozygous AOX transgene. Wild-type and heterozygous Bcs1lp.S78G littermates were 
used as healthy controls. The AOX transgene is in the Rosa26 locus and it is ubiquitously 
transcribed under a strong synthetic CAG promoter.219 In the original publication, the 
Bcs1lp.S78G  homozygotes are referred as GRAC (GRACILE) and when they express AOX as 
GROX (GRACILE + AOX).
The experimental cohorts of mice comprised four genotypes: 1) wild-type (WT), 2) 
Bcs1lWT;Rosa26AOX, 3) Bcs1lp.S78G and 4)  Bcs1lp.S78G;Rosa26AOX. We used one set of mice (n= 
18-21/genotype) to estimate the lifespan. Two other sets of mice were euthanized at 5 
and 6.5 month of age to collect samples prior and at the terminal stage of the Bcs1lp.S78G 
homozygotes, respectively. In addition, we transferred one experimental cohort to German 
Mouse Clinic ( ) for phenotype screening between ages of 56 and 112 
days (n=20/genotype).
8.6 Lund University 6JBomTac and Harlan 6JCrl hybrid mice
To generate mice differing in their mtDNA but having equalized nuclear DNA, we 
crossbred Bcs1lp.S78G heterozygotes from congenic Lund University C57BL/6JBomTac and 
commercial C57BL/6JCrl (Harlan) substrains. Given the congenic nature of the substrains, 
the outcome of this crossbreeding experiment was first generation (F1) hybrid mice having 
the parenteral homozygous nuclear DNA differences in a heterozygous state and the 
mtDNA determined by the maternal background. Subsequently, we backcrossed the Lund 
University C57BL/6JBomTac mtDNA genome onto the C57BL/6JCrl nuclear background 
for independent replications of the key parameters.
36
Table 1. List of methods
Method Study
Histochemistry
Paraffin-embedded sections I, II, III, IV
Cryosections I
Hematoxylin and eosin I, II, III IV
Periodic acid-Schiff I, II, IV
Sirius Red I, II, III IV
Oil-Red-O I
DAB-enhanced Prussian Blue II
Immunostaining I, II, III IV
Automated image quantification I, II, III, IV
Electron microscopy I, III
Clinical chemistry
Blood glucose I, II, III, IV
Blood lactate I
Blood -hydroxybutyrate I
Plasma liver enzyme activities I, II, III
Urine albumin and creatinine III
Echocardiography III
Protein  analyses
SDS-PAGE and Western Blot I, II, III, IV
Blue-Native PAGE and Western blot I, III, IV
Proteomics II
Mitochondrial enzyme activity measurements I, II, III, IV
Molecular dynamics simulations IV
Pulse EPR spectroscopy IV
Gene expression analyses I, II, IV
qPCR I, II, IV
Transcriptomics I, II*, III
Whole genome sequencing IV
Lipid analyses
Liver triglycerides I
Liver free fatty acids I
Metabolite analyses
Plasma metabolomics I, II
Liver metabolomics II*, III
ATP measurements IV
NAD+ and NADH measurements II
Mitochondrial respirometry II, III, IV
Measurement of mitochondrial H2O2 emission III, IV
Indirect calorimetry (CLAMS) III, IV
* Transcriptomics and metabolomics data from studies I and III 
were also utilized in the study II.
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9 RESULTS AND DISCUSSION
9.1 mtDNA background alters the disease course of Bcs1lp.S78G mice 
(Studies I-IV)
The Bcs1lp.S78G knock-in mutant mice were generated and characterized in mixed 129/
SvEvTac:C57BL/6 as well as on an in-house congenic C57BL/6JBomTac-derived background 
in Lund University, Sweden.18,116,223 For the studies I-IV, we transferred heterozygous 
Bcs1lp.S78G embryos to University of Helsinki and backcrossed the mutation into a commercial 
C57BL/6JCrl substrain. The early-onset phenotypes of the homozygotes were similar as 
described in Lund University. However, to our surprise, the homozygotes survived the 
early-onset metabolic crisis at one month of age. In studies I and III, we characterized the 
novel late-onset phenotypes. The study IV identified a novel mtDNA variant (mt-Cybp.D254N) 
in the original Lund University mouse colony as the determinant of the short lifespan of 
the Bcs1lp.S78G homozygotes.
9.2 Ketogenic diet attenuates CIII deficiency-related hepatopathy (I)
Ketogenic diet has been suggested to induce a starvation-like adaptive response leading 
to enhancement of mitochondrial function.162,163 Based on positive findings in cell culture 
models164–166 and in a mitochondrial myopathy model167, we set out to test ketogenic diet 
as a therapy for CIII deficiency-related hepatopathy. 
9.2.1 Bcs1lp.S78G mice tolerate carbohydrate restriction and readily sustain 
nutritional ketosis
Hypoketotic hypoglycemia is a phenotype of Bcs1lp.S78G mice.117,158 Therefore, we hypothesized 
that ketogenic diet could decrease the dependence on glycolysis by forcing the cells to 
use fatty acids and ketone bodies. On the other hand, CIII deficiency may compromise 
mitochondrial fatty acid oxidation, which could render the mice intolerant to a high-fat 
ketogenic diet.223 We found that the Bcs1lp.S78G mice readily adapted to ketogenic diet as 
shown by the induction of ketogenesis and the maintenance of blood glucose at a similar 
level as on standard chow (I, Table 2). Ketogenic diet also did not affect the growth of mutant 
mice (I, Supplementary Fig.1). In wild-type mice, ketogenic diet induced ketosis during the 
juvenile period (<P50) (I, Table1), whereas adult mice exposed for approximately 10 weeks 
to ketogenic diet were no longer in ketosis. The lack of sustained ketosis in wild-type mice 
was likely due to the relatively mild protein restriction, as dietary protein inhibits ketosis 
in rodents.149 Bcs1lp.S78G mice responded differently. They remained in ketosis during the 
whole follow-up (β-hydroxybutyrate, >4.5 mM). 
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9.2.2 Ketogenic diet attenuates markers of acute and chronic liver damage
During study I, we extended the characterization of the liver pathology of Bcs1lp.S78G mice. 
Liver disease progression was also the primary outcome for the ketogenic diet intervention. 
Table 2 summarizes the findings and the effect of ketogenic diet. Ketogenic diet attenuated 
most of the histopathological findings including fibrosis, stellate cell activation, hepatocyte 
death, and hepatic progenitor cell response (I, Fig. 1-2). The liver enzyme activities in 
plasma were also attenuated (I, Table1). As expected, ketogenic diet did not improve 
glycogen depletion (I, Supplementary Fig. 2). Ketogenic diet increased liver triglyceride 
content in wild-type and mutant mice but did not cause overt steatosis (I, Fig 1F). It is of 
note that some ketogenic diet formulations do cause pathological steatosis in mice due to 














Table 2. Effect of ketogenic diet on 
liver disease progression in Bcs1l p.S78G  mice
One of our novel histological findings was hepatic progenitor cell response in mutant 
mice (I, Fig. 1A, Fig. 2A, and Supplementary Fig. 4). In the literature, this finding is also 
described as oval cell hyperplasia or ductular reactions.224 Its presence correlates with the 
severity of hepatopathy in humans.225 In experimental models, liver regeneration does not 
evoke an overt hepatic progenitor cell response unless a simultaneous cytotoxic insult or 
hepatocyte senescence is present.226,227 Of note, the livers of Bcs1lp.S78G mice accumulated 
ceroid-lipofuscin-like material suggesting increased cellular senescence, which was 
attenuated by ketogenic diet (I, Supplementary Fig 12). Normally liver regenerates by 
hypertrophy and proliferation of hepatocytes with little contribution from the progenitor 
cells.226 Therefore the results suggest that the hepatocytes of  Bcs1lp.S78G mice were prone 
to senescence and had insufficient mitotic capacity. The hepatic progenitor cell response 
is visible in H&E-stained sections as expansion of non-parenchymal cells with oval-like 
morphology. Occasionally these cells form bile duct-like structures (ductular reactions) 
outside portal areas. As the hepatic progenitor cells are able to differentiate into 
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hepatocytes and cholangiocytes, they express antigens of both compartments, which allows 
their visualization by immunostaining against bile duct markers such as cytokeratin-7. 
Importantly, ketogenic diet essentially prevented the formation of ductular reactions and 
aberrant cytokeratin-7 immunoreactivity at juvenile period (postnatal days 40-45, P40-45) 
and significantly decreased them at a later time point (P95) (I, Fig. 1A, Fig 2A). 
9.2.3 Ketogenic diet partially normalizes hepatic mitochondrial structure and 
function
As ketogenic diet has been suggested to increase mitochondrial biogenesis,162,167 we 
quantified the hepatic expression of Ppargc1a (encoding PGC-1α) and genes encoding 
for mitochondrial proteins (I, Fig 4G,I and Supplementary Fig. 8). To assess relative 
mitochondrial mass, we quantified mtDNA copy number, citrate synthase activity and 
amounts of several mitochondrial proteins (I, Fig 4A-C). None of these indicated that 
ketogenic diet increased mitochondrial biogenesis in the liver. However, PGC-1α was 
induced at mRNA level in the mutant mice independently of the diet, as was citrate 
synthase activity, and some mitochondrial proteins in liver lysates, suggesting increased 
mitochondrial content. In contrast, ketogenic diet increased skeletal muscle citrate 
synthase activity, a commonly used mitochondrial marker enzyme, as also reported in a 
mitochondrial myopathy model167. However, ketogenic diet did not increase mitochondrial 
protein levels in muscle homogenates, suggesting unaltered mitochondrial mass.
Despite no evidence of increased mitochondrial biogenesis, ketogenic diet improved the 
assembly and activity of CIII in liver mitochondria (I, Fig. 3, Fig. 4F-F). Previously,  in 
cultured cells with a homoplasmic mutation affecting mitochondrial leucine tRNA, ketone 
bodies improved assembly and activity of CI.166 In these cells, the improvement could have 
been due to an increase in mtDNA copy number. In the case of nuclear Bcs1l mutation, 
the mechanism remains elusive. A robust normalization of mitochondrial ultrastructure 
by ketogenic diet, however, indicated a global improvement in mitochondrial condition 
(I, Fig. 3). Ketogenic diet has also corrected mitochondrial morphology in a mouse model 
of myopathy.167 Several studies have demonstrated that mitochondrial function and 
morphology are tightly connected.228–230
9.2.4 Mechanistic insights from liver transcriptomics
To gain deeper understanding of the effect of ketogenic diet and the Bcs1lp.S78G mutation, 
we performed liver transcriptome analysis. Many of the most upregulated genes due to 
the Bcs1lp.S78G mutation were related to macrophage activation and glutathione-mediated 
detoxification (I, Fig. 6 and 7). Ketogenic diet normalized several of these changes. 
Moreover, immunohistochemical analyses showed a clear change in macrophage 
populations and morphology in the Bcs1lp.S78G mutants, and attenuation by ketogenic diet 
(I, Fig. 2). The polarization of macrophages into different subclasses involves a large shift 
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in energy metabolism and mitochondrial function.222 The proinflammatory, classically 
activated, M1 macrophages are highly glycolytic whereas the alternatively activated, anti-
inflammatory, M2 macrophages use OXPHOS. Macrophage polarization in the context of 
CIII deficiency is a largely unstudied topic, but, for example, a loss of complex I activity 
in mice can cause systemic inflammation231, and the complete loss of CIII activity in 
regulatory T cells is sufficient to cause lethality in mice232. Interestingly, liver macrophages 
express the β-hydroxybutyrate receptor HCAR2, and β-hydroxybutyrate administration 
has ameliorated acute liver toxicity by promoting M2 macrophage polarization via HCAR2-
mediated signaling.233 In addition, β-hydroxybutyrate modulates macrophage activation 
and suppresses inflammation by inhibiting NLRP3 inflammasome activation.175
The transcriptome data also predicted repressed tryptophan catabolism and the related 
NAD+ de novo biosynthesis. We investigated these changes further in study II.
9.3 NAD+ metabolism in CIII-deficient mice (II)
When we initiated this study in 2014, non-pellagra metabolic NAD+ depletion was a recently 
recognized condition and the NAD+-repletion therapies were just emerging. Promising 
results with the NAD+ precursor NR in two mouse models of mitochondria myopathy130,131 
prompted us to study NAD+ metabolism in a CIII deficiency-related hepatopathy. 
9.3.1 Repressed NAD+ biosynthesis and NAD+ depletion in Bcs1lp.S78G mice
In study I, we found hepatic gene expression changes in young (P45) Bcs1lp.S78G mice 
suggesting repressed tryptophan catabolism and nicotinic acid utilization for NAD+ 
biosynthesis. These changes were also present in older (P150) mutant mice in the liver 
but also in the kidney (Fig. 8) (II, Fig. 1). Liver and kidney are the main organs utilizing 
tryptophan and nicotinic acid for NAD+ biosynthesis.190–192 Endogenously, other tissues 
rely mainly on nicotinamide as a NAD+ precursor. In contrast to the transcriptionally 
repressed de novo NAD+ biosynthesis, the gene expression of the rate-limiting enzyme, 
Nampt, in the NAD+ salvage from nicotinamide was increased in the liver and kidney, 
suggesting heightened need for NAD+. Indeed, we found decreased hepatic NAD+ levels 
in Bcs1l mutants at P150.  Later, we have verified the hepatic NAD+ depletion also in much 
younger (P33-35) Bcs1lp.S78G mice and in the mutants on the mtDNA background with the 
short survival (Fig. 9, unpublished results). Interestingly, the NAD+ depletion was more 
pronounced in the juvenile Bcs1lp.S78G mice. We also analyzed protein poly-ADP ribosylation 
and CD38 expression as these may significantly contribute to NAD+ consumption (II, Fig. 
1E-G, Supplementary Fig. 2). These were unchanged across the genotypes, which suggest 









































Figure 8. Expression of NAD+ biosynthesis-related genes in the liver of Bcs1lp.S78G mice. The 
bolded colors indicate significantly (p<0.05) upregulated (red) or downregulated (blue) genes 
in Bcs1lp.S78G mice at postnatal day 150 (P150) as compared to wild-types (n=5 for wild-types 























Figure 9. Hepatic NAD+ levels in juvenile (P33-35) Bcs1lp.S78G mice. The measured samples were 
from study IV F1 hybrid mice with and without the mt-Cybp.D254N variant. The error bars represent 
95% confidence interval of the mean. An enzymatic assay with cyclic signal amplification based 
on alcohol dehydrogenase and a tetrazolium dye reduction was used for the measurements.
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9.3.2 NR supplementation does not affect the disease progression
With an aim to correct the NAD+ depletion, we initiated a randomized controlled 
intervention with NR supplementation starting at weaning (P21) and lasting for 13 weeks. 
Behavioral scoring and monitoring of weight loss, performed in blinded fashion, showed 
no improvement in the condition of the Bcs1lp.S78G mice (II, Fig. 3A). This was in line with 
unaltered hepatopathy progression as evaluated by quantification of liver fibrosis, hepatocyte 
death, ductular reactions, and liver enzyme activities in plasma (II, Fig. 3C-G). We also 
repeated the intervention in Bcs1lp.S78G mice on the mt-Cybp.D254N mtDNA background with 
a more severe disease progression and assessed survival as the main outcome parameter 
(II, Fig. 3H). The survival was unaffected. 
9.3.3 NR alters hepatic NAD+ metabolome but does not correct the NAD+ 
depletion
A targeted liver NAD+-metabolome analysis verified the decreased NAD+ in Bcs1lp.S78G mice 
(II, Fig 2A). However, this was unaffected by NR administration. Neither did NR affect 
the nicotinamide or ADP-ribose concentrations (II, Fig. 2C,H), two metabolites of NAD+ 
consuming processes234. A clear increase in three degradation metabolites of nicotinamide by 
NR, nevertheless, suggested that NR increased metabolic fluxes involving nicotinamide (II, 
Fig. 2D-F). NR also increased nicotinic acid adenine dinucleotide (NAAD) concentration 
(II, Fig. C). In light of the most recent understanding of mammalian NAD+ biosynthetic 
routes,190,192 the increased NAAD  likely reflects the proportion of NR converted first to 
nicotinamide then to nicotinic acid by the gut microbiota and then metabolized by the 
liver via the Preiss-Handler pathway to NAAD. The increase in NAAD concentration 
also suggests increased biosynthetic flux towards NAD+.234 Figure 10 summarizes the 




































Figure 10. Effect of NR on NAD+ and related metabolites in the liver of Bcs1lp.S78G mice. The 
bolded red percent values indicate significantly (p<0.05) increased metabolite concentrations 
(n=5/group). 
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supplementation did not increase hepatic NAD+ concentration, at least at the fixed end 
point, could have been due to the role of liver in maintaining circulating nicotinamide to 
support NAD+ biosynthesis in extrahepatic tissues. A recent study on NMN in CI-deficient 
mice (Ndufs4 knockout) showed similar refractory NAD+ depletion in liver, heart and brain 
but efficient NAD+ repletion in skeletal muscle.206
9.3.4 Mitochondria-related parameters remain unchanged by NR administration
In line with the lack of effect on hepatic NAD+, NR did not alter mitochondrial respiratory 
function or mitochondrial mass (II, Fig. 4A-C). Furthermore, we performed a label-
free quantitative proteomics from liver mitochondria. Out of 572 quantified annotated 
mitochondrial proteins none were differentially expressed in Bcs1lp.S78G mice due to NR 
administration at false-discovery rate (FDR) of 0.05 (II, Supplementary Table 1). As a 
comparison, the Bcs1lp.S78G mutation altered the expression of one quarter of the quantified 
mitochondrial proteins (fold change >1.4, FDR-adjusted p value < 0.05).
9.3.5 NAD+-independent regulation of SIRT1 and SIRT3 in Bcs1lp.S78G mice
SIRT1 and SIRT3 are the main targets of NAD+-repletion therapies.128 These two sirtuin 
deacetylases respond to alterations in cellular energy state by monitoring NAD+ levels. 
The Bcs1lp.S78G mice have a profoundly altered energy metabolism involving  hypoglycemia, 
and depletion of glycogen and fat stores (Study I, and18,117,158). These manifestations were 
unaffected by NR supplementation (II, Fig. 5A-B). Increase in SIRT1 activity due to elevated 
cellular NAD+ is only one branch of cellular signals that try to balance energy homeostasis 
upon nutrient scarcity.11 Another key regulator is AMPK, which monitors cellular AMP/
ATP and ADP/ATP ratios. The regulatory network upstream and downstream of SIRT1 
and AMPK are complex and these regulators also regulate each other. Glucose deprivation 
can activate AMPK independently of changes in adenine nucleotides.235 Accordingly, we 
found increased activating phosphorylation of AMPK in the liver of Bcs1lp.S78G mice (II, Fig. 
5C and Supplementary Fig. 5A). Moreover, PKA/cAMP signaling cascade, triggered e.g. 
by glucagon and adrenergic exposure, stimulates SIRT1 activity and decreases its affinity 
for NAD+.236  Hepatic cAMP levels were increased in Bcs1lp.S78G mice (II, Fig. 5E). cAMP is 
also a direct activator of SIRT3.237 Interestingly, Bcs1lp.S78G mice had decreased acetylation 
of the SIRT3 target protein SOD2 in the liver, suggesting increased SIRT3 activity despite 
the decreased NAD+ levels. (II, Fig. 5F). In addition, AMPK  can increase  SIRT1 activity 
indirectly through the upregulation of the rate-limiting NAMPT in the NAD+ salvage 
pathway.238 Bcs1lp.S78G mice showed increased hepatic gene and protein expression of 
NAMPT (II, Fig. 1B, Fig. 5D), but obviously this upregulation was insufficient to maintain 
normal NAD+ levels. 
A key downstream target of both SIRT1 and AMPK in the regulation of mitochondrial 
function is PGC-1α.119 As already seen in study I, PGC-1α was upregulated at transcript 
level in Bcs1lp.S78G mice (II, Fig. 5G). This upregulation was also present at protein level (II, 
Fig. 5G and Supplementary Fig. 5B). One of the aims of NAD+ repletion therapies is to 
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enhance oxidative metabolism including fatty acid oxidation.129,239 At transcriptome and 
mitochondrial proteome level the Bcs1lp.S78G mice showed repressed de novo lipogenesis and 
upregulated fatty acid oxidation independently of NR (II, Fig. 5I-L). 
Sirtuins mainly function as lysine deacetylases.179 Cellular protein acetylation is balanced 
by acetylation and deacetylation. The acetylation of lysine residues in proteins requires 
acetyl-CoA, the concentration of which in cytoplasm and nucleus largely depends on 
the activity of ATP citrate lyase (ACLY).240 In the liver of Bcs1lp.S78G mice, acetyl-CoA 
concentration was one fourth of that in wild-type mice, and ACLY was downregulated at 
transcript and protein level (II, Fig. 6A-C). The analysis of lysine acetylation in the liver 
showed no aberrant acetylation in Bcs1lp.S78G mice at P115 (II, Fig.6 D). However, at P30 in 
Bcs1lp.S78G mice on mt-Cybp.D254N background the acetylation of some proteins was increased 
(II, Supplementary Fig. 6). Nevertheless, NR administration did not affect global protein 
acetylation in either mouse cohort.
In summary, many canonical metabolic events associated with SIRT1 and SIRT3 activation 
in NAD+-targeting therapies were already upregulated in the Bcs1lp.S78G mice and were not 
further stimulated by NR supplementation.
9.4 Late-onset phenotypes and the effect of AOX (III)
AOXs are non-mammalian mitochondrial terminal oxidases that can facultatively bypass 
the CIII-CIV segment of the respiratory electron transfer.212 In conditions of CIII or CIV 
blockade, AOX-mediated respiration maintains quinol oxidation and electron transfer, 
albeit with decreased OXPHOS capacity. We crossbred Bcs1lp.S78G mice with mice expressing 
Ciona intestinalis alternative oxidase219 with the aim to alleviate decreased respiratory 
electron transfer-related metabolic disturbances. In this study, we also characterized the 
late-onset phenotypes of the Bcs1lp.S78G mice. An extensive description of the effect of AOX 
on Bcs1lp.S78G mice is presented in the thesis of Dr. Rajendran.241 Here, a summary and 
relevant parts are discussed in relation to the studies I, II and IV.
9.4.1 Chronic liver and kidney disease in Bcs1lp.S78G mice
Neonatal liver and kidney disease are the most prominent manifestations of the 
GRACILE syndrome.17,95 Similarly, the Bcs1lp.S78G mice show early-onset (P24-26) 
rapidly progressing liver and kidney disease (I, II, IV and18). In contrast to the Lund 
University C57BL/6JBomTac Bcs1lp.S78G mice with juvenile lethality (II, IV and18,116), the 
Bcs1lp.S78G mice on C57BL/6JCrl background did survive the early-onset metabolic crisis 
(I, II). In the study III, we determined their median lifespan to be 210 days (III, Fig. 1B). 
Strikingly, AOX expression extended the median lifespan to 590 days. At the end stage, the 
Bcs1lp.S78G mice, with and without AOX transgene, showed prominent liver and kidney 
fibrosis, indicating chronic tissue damage (III, Fig. 2C, D). The increase in plasma liver 
enzyme activities was similar or somewhat attenuated in comparison to measurements 
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from earlier time-points in studies I and II (Fig. 11A, B), suggesting an on-going damage 
but eventual stabilization of the liver condition. AOX did not affect these parameters of liver 
damage at P200. Interestingly, the hepatic Gdf15 expression, a marker of mitochondrial 
dysfunction and overall morbidity,242 was elevated several-fold in young (P30-45) Bcs1lp.S78G 
mice (I, IV), but at the age of 150 days it was similar as in wild-types (Fig. 11C). 
Despite the extension of lifespan of Bcs1lp.S78G mutants  and verified AOX activity in isolated 
liver mitochondria (III, Fig. 6H), AOX had little effect in the liver on tissue histology (Fig. 
2C), mitochondrial morphological aberrations (III, Fig. 3C-F), or transcriptome changes 
(III, Fig. 4) in mice older than 150 days, suggesting amelioration of the condition of other 
tissues. In the kidneys of Bcs1lp.S78G mice, AOX clearly had an effect. AOX normalized the 
kidney atrophy (III, Fig. 2A-B), some histological lesions (III, Fig. 2C-D and Supplementary 
Fig. 1), and mitochondrial morphology in proximal tubules (III, Fig. 3B-F). However, AOX 
had minimal effect on albuminuria (III, Fig. 2H) and global transcriptome changes (III, 
Fig. 4). In fact, the expression of many highly up-regulated genes due to the Bcs1lp.S78G 
mutation were either unaffected or further induced by AOX (III, Fig. 4L). These results 
suggested that the dramatic extension of lifespan by AOX was not predominantly related 
to improved kidney function













































Figure 11. A meta-analysis of plasma liver enzyme activities (A-B) and hepatic gene expression 
of Gdf15 (C) from studies I-IV. The bar graphs and their error bars represent mean value and 
2 SDs. The dashed lines represent average values in wild-type mice.
9.4.2 Late-onset lethal cardiomyopathy and its prevention by AOX
Cardiomyopathy has not been reported in patients with BCS1L mutations. However, it 
remains unclear whether those patients who do survive into adulthood will eventually 
develop a cardiomyopathy. Similarly, we have not observed any indications of 
cardiomyopathy in young (<P120) Bcs1lp.S78G mice (I, II, IV, and18). In addition, the CIII 
deficiency in the juvenile period (<P40) of the mutant mice is less pronounced in the heart 
(50% of wild-type) in comparison to the liver (20-35% of wild-type) (IV and18). However, 
when we collected the end-stage samples (>P190), the immediate observation was a dilating 
cardiomyopathy and its prevention by AOX (III, Fig. 2A). The echocardiography analyses 
showed failing heart few days before the terminal stage, indicating cardiomyopathy as 
the cause of the death (III, Fig. 2E-F). In contrast, at P150, before the macroscopical or 
histological alterations, only minimal functional defects in the heart were observable (III, 
Supplementary Fig. S1). CIII activity was 35% of wild-type values (III, Fig. 6F), which 
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compromised OXPHOS (III, Fig. 6 I-J). The mitochondrial morphology was also disturbed 
(III, Fig. 3 B-F). In contrast, the heart mitochondria of AOX-expressing Bcs1lp.S78G mice 
had normal ultrastructure (III, Fig. 3 B-F) and were able to maintain wild-type respiratory 
electron transfer (III, Fig. 6 I-J). Moreover, AOX caused a global normalization of cardiac 
transcriptome at P150 (III, Fig. 4), a time point when the hearts of Bcs1lp.S78G mice were 
still functionally asymptomatic. 
One peculiar effect of AOX on Bcs1lp.S78G mice was the increased RISP amount in CIII 
and improved CIII activity in the heart mitochondria (III, Fig. 6A-C, F). Even more 
peculiar was the totally opposite response in the liver and kidney mitochondria. In study 
I, we also found that ketogenic diet improved the CIII assembly and activity in the liver. 
Together these results imply that the Bcs1lp.S78G-related CIII assembly defect is not a static 
condition but affected by still unknown factors. One potential regulator of BCS1L function, 
and possibly affected by AOX, is mitochondrial ATP/ADP ratio. In yeast, mutations 
that decrease the ATP hydrolysis activity of ATP synthase can compensate certain Bcs1 
mutations.243 At the same time with our study, Dogan et al. studied the effect of AOX on 
conditional Cox15 knockout mice with skeletal muscle-specific CIV deficiency.244 In their 
model, AOX expression decreased mitochondrial mass, exacerbated IV deficiency, and 
decreased the lifespan. We did not find any indications of skeletal muscle-related adverse 
effects (our behavioral scoring and independent phenotype screening by German Mouse 
Clinic). 
In summary, AOX-mediated respiration in a severe CIII deficiency was sufficient to maintain 
largely normal function of the heart, a tissue that has perhaps the highest requirement 
for OXPHOS in the body. Importantly, AOX provided a long-term protection from the 
cardiomyopathy as there was no sign of cardiomyopathy even in those mice that lived past 
600 days (III, Supplementary Figure EV2).
9.5 A homoplasmic mt-Cyb variant exacerbates CIII deficiency in 
Bcs1lp.S78G mice (IV)
During the studies I-III, we observed an approximately five-fold difference in the lifespan 
of Bcs1lp.S78G mice in two closely related congenic substrains. We found out that the original 
mouse colony in Lund University, Sweden, had been maintained for years without 
obtaining new breeding mice from any commercial source. Therefore, we suspected that a 
genetic drift had taken place in the original mouse colony and proceeded to whole genome 
sequencing to identify potential Bcs1lp.S78G-interacting genetic changes. 
9.5.1 Identification of a novel mtDNA variant 
Whole genome sequencing identified 4449 homozygous single-nucleotide polymorphisms 
or insertions or deletions differing between the substrains (Lund University 
C57BL/6JBomTac vs Harlan C57BL/6JCrl). Only eight of these were in the coding-regions 
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of genes. Of these eight, two were synonymous and five potentially biological relevant 
changes had no obvious connection to mitochondrial function or energy metabolism 
(IV, Supplementary Table 1). However, one single-nucleotide change of Lund University 
substrain was in mtDNA (m.G14904A) and not present in any Mus musculus sequence 
in data bases. This variant changes a highly conserved negatively charged residue in MT-
CYB (p.D254N), the essential catalytic subunit of CIII (IV, Fig. 1A). Moreover, the change 
is in a region known to interact with RISP, which assembly is compromised in BCS1L 
mutations. Genotyping of old DNA samples from the past generations from the Lund 
University colony consistently verified the presence of mt-Cybp.D25N4 since May 2008 (IV, 
Supplementary Fig. 1A). Interestingly, two early-generation female mice had given progeny 
carrying both wild-type and variant mtDNA, suggesting initial heteroplasmy. However, 
no signs of heteroplasmy were detectable in different somatic tissues in later generations 
(IV, Supplementary Fig. 1B). In line with the homoplasmic nature of the variant, the 
congenic Lund University colony Bcslp.S78G homozygotes show highly consistent lifespan of 
approximately 1 month (Study II, and116,117)
After finding this obvious candidate gene, we utilized the maternal inheritance of mtDNA 
and crossbred Bcs1lp.S78G heterozygotes to obtain F1 hybrid mice with equal nuclear DNA but 
differing in their mtDNA (IV, Fig 1B). The Lund colony females consistently transmitted 
the short-survival phenotype to the Bcs1lp.S78G homozygotes, but the males did not (IV, 
Fig 1C). As the mt-Cybp.D254N variant was the only difference in the mtDNA between the 
substrains, this variant is the cause of the survival difference. In line with the decreased 
survival, mt-Cybp.D254N aggravated the kidney disease and caused massive hepatocyte death 
at the end stage in Bcs1lp.S78G homozygotes (IV, Fig. 1G-H Supplementary Fig. 3-4).
9.5.2 Mt-Cybp.D254N decreases CIII activity below survival threshold in 
Bcs1lp.S78G mice
The Bcs1lp.S78G homozygotes of Lund University colony show a progressive loss of CIII 
activity.18 At birth, the homozygotes have almost normal CIII activity in the liver but at 
the time of expected spontaneous death it is less than 25% of wild-type values. In the 
University of Helsinki colony, we have not seen as dramatic loss of CIII activity (study 
I and III). The genetically comparable F1 mice allowed us to compare more directly the 
effect of mt-Cybp.D254N variant. In the liver, kidney, skeletal muscle and heart of Bcs1lp.S78G 
mice, mt-Cybp.D254N caused a further decrease in CIII activity (IV, Fig.2, Supplementary 
Fig. 5). We also measured CIII activity in mice that we had backcrossed onto C57BL/6JCrl 
background. In these mice also, mt-Cybp.D254N exacerbated the CIII deficiency. The mt-
Cybp.D254N did not cause consistently measurable difference in CIII activity in Bcs1l wild-
type mice in liver, kidney, or skeletal muscle (IV, Fig.2, Supplementary Fig. 5). However, 
three different sample sets showed decreased cardiac CIII activity in Bcs1l wild-type mice 
carrying the mt-Cybp.D254N variant.
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9.5.3 Mt-Cybp.D254N restricts RISP head domain movement
Next, we set out to investigate how the mt-Cybp.D254N variant affects CIII function. The MT-
CYB is an essential structural core of CIII and the D254N amino acid change is in a region 
interacting with RISP, therefore we used blue-native gel electrophoresis and Western blot 
analyses to investigate whether it interferes with RISP assembly into CIII (IV, Fig.3). As 
expected (study I, and18,116), the liver and kidney mitochondria of Bcs1lp.S78G mice showed 
diminished amount of RISP in CIII. However, mt-Cybp.D254N variant did not significantly 
alter CIII amount or assembly.  
Because the CIII amount and composition were unaffected, we sought alternative 
explanations for the synergistic decrease in CIII activity due to Bcs1lp.S78G and 
mt-Cybp.D254N. Based on the crystal structures of CIII, the RISP head domain brushes the 
MT-CYB ef loop containing the D254N substitution during the electron transfer between 
the Qo site and cytochrome c1 (IV, Fig. 5A-C).  Molecular dynamics simulation provided 
a further insight into the interaction between mt-Cybp.D254N and RISP. The simulations 
suggested that the D254N restricts the conformational flexibility of T250-V270 segment 
in the mt-CYB ef loop with simultaneous decrease in the mobility of RISP P136-W146 
residues (IV, Fig. 5D-G). These results predict that D254N could affect RISP head domain 
movement during the electron transfer.
To test the computational prediction, we employed a Rhodobacter capsulatus model in 
which the cytochrome b can be mutagenized and the cytochrome bc1 complex isolated.245 
In this organism, D258N substitution, equivalent to the Mus musculus D254N, supported 
cytochrome bc1-dependent photosynthetic growth and did not alter the maximal 
enzymatic activity (IV, Supplementary Table 2). The purified cytochrome bc1 complex 
from Rhodobacter capsulatus allowed the monitoring of RISP head domain movement 
using pulse electron paramagnetic resonance (EPR) spectroscopy. In this method, the 
phase relaxation of RISP Fe-S cluster in proximity to oxidized heme bL of cytochrome b 
gives a signal enhancement that allows the monitoring of RISP head domain distribution 
between Qo and cytochrome c1 positions.89,245 In native enzyme preparations, the RISP head 
domains are equally distributed between the two positions.245 The D258N substitution 
shifted the RISP head domain positional distribution towards the Qo site (IV, Fig. 5H-I). 
In summary, the CIII kinetics disturbance due to mt-Cybp.D254N was subtle, but it clearly 
affected a rate-limiting step in Bcs1lp.S78G mice with insufficient RISP incorporation into CIII. 
Moreover, mt-Cybp.D254N clearly affected cardiac CIII activity in Bcs1l wild-type mice. CIII is 
inactive without RISP because the first electron-transfer reaction does not occur. However, 
as CIII is a dimer, it is possible that the Bcs1lp.S78G mice have heterodimers containing only 
one RISP. Artificial bacterial cytochrome bc1 heterodimers with only one active Qo site have 
almost wild-type enzyme activity due to the inter-monomer electron transfer via the two 
closely located bL hemes.246,247 Evidence also exits that the CIII dimer may operate under 
half-of-the-sites reactivity mechanisms in which only one Qo site operates at any time,246 
a process that might be under physiological regulation.248 It is tempting to speculate that 
the mt-Cybp.D254N variant might affect a rate-limiting step in heterodimers containing single 
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RISP or in wild-type cardiac mitochondria in which CIII might harbor posttranslational 
modifications that modify the CIII processivity. 
9.5.4 Metabolic consequences of mt-Cybp.D254N mtDNA background
To assess the effect of mt-Cybp.D254N variant on mitochondrial bioenergetics, we subjected 
liver and kidney mitochondria to respirometry analysis (IV, Fig. 4, Supplementary Fig. 
7-9). In line with the exacerbated CIII deficiency, Bcs1lp.S78G;mt-Cybp.D254N mice showed a 
further decrease in CI and CII-mediated phosphorylating respiration (IV, Fig. 4A). In Bcs1l 
wild-type mice, mt-Cybp.D254N did not affect this parameter. Addition of an ATP-synthase 
inhibitor to induce high-membrane potential state and leak respiration, however, revealed a 
Bcs1lp.S78G-independent decrease in oxygen consumption by mt-Cybp.D254N (IV, Fig. 4B). The 
dissipation of membrane potential abolished this mt-Cybp.D254N-related difference in oxygen 
consumption in Bcs1l wild-type mice (IV, Fig. 4C). Due to decreased leak respiration, the 
Bcs1l wild-types carrying mt-Cybp.D254N also showed increased electron-transfer coupling 
efficiency (IV, Fig. 4D-E, Supplementary Fig. 7). As CIII is a proton translocase, the 
reduced leak respiration suggests that mt-Cybp.D254N decreases proton leakage at CIII, or 
indirectly elsewhere, or affects a rate-limiting step when the enzyme is operating against 
high membrane potential.
The Qo site of CIII is one potential source of mitochondrial ROS.60 However, mutations that 
cause RISP head domain to predominantly locate to Qo site, similar to mt-Cybp.D254N, tend to 
decrease superoxide production.64 In line with this, the D258N substitution in Rhodobacter 
capsulatus did not detectably affect the maximal antimycin-induced superoxide production 
by the enzyme (IV, Supplementary Table 2). Neither did we observe altered hydrogen 
peroxide emission by isolated state 3 respiring mouse mitochondria with succinate as 
substrate and reverse-electron flow blocked with rotenone (IV, Supplementary Fig. 11). 
However, these results do not exclude altered ROS production elsewhere in the electron 
transfer, or differences after induction of high mitochondrial membrane potential. 
To assess whether the subtle disturbance in mitochondrial bioenergetics due mt- 
Cybp.D254N affects whole-body metabolism, we subjected the mice to indirect calorimetry. The 
mt-Cybp.D254N;Bcs1lp.S78G mice were clearly a distinct group showing low respiratory exchange 
ratio implying increased fatty acid oxidation (IV, Fig. 6A,B). Their energy expenditure was 
also decreased (IV, Fig. 6C). The daytime measurements did not distinguish the three other 
genotypes from each other (IV, Fig. 6A-C). However, during nighttime, when the mice 
are most activity, both the mt-Cybp.D254N variant and the Bcs1lp.S78G mutation caused a similar 
decrease in respiratory exchange ratio and energy expenditure in comparison to wild-type 
mice. Differences in physical activity did not explain the results (IV, Supplementary Fig. 
14). The unexpectedly large effect of mt-Cybp.D254N on whole-body metabolism in apparently 
healthy mice led us to measure hepatic gene expression of two well-established markers 
of mitochondrial dysfunction, Fgf21 and Gdf15.242  In study I, we showed that both of 
them are upregulated in the liver of Bcs1lp.S78G mice (I, Fig. 4H). The mt-Cybp.D254N variant 
did not further increase Fgf21 or Gdf15 expression in Bcs1lp.S78G mutants (IV, Fig. 6D,E). 
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However, surprisingly, the mt-Cybp.D254N variant on its own induced Fgf21 expression to a 
similar degree as the pathogenic Bcs1lp.S78G mutation (IV, Fig. 6D). In normal physiology, 
FGF21 is mainly a hepatocyte-derived stress-inducible paracrine and endocrine factor 
regulating energy metabolism.153 In mitochondrial dysfunction, mitochondrial integrated 
stress response induces FGF21 expression in the affected tissues.249 Figure 12 summarizes 
the identified effects of mt-Cybp.D254N variant.
mt-Cybp.D254N
RISP head domain (Fe-S cluster)
“stuck” towards the Qo site
Wild-type Bcs1l 
Uncompromized  RISP assembly:
Fully-assembled CIII dimers
Bcs1l p.S78G
RISP assembly defect 
Heterogenous pool of fully-assembled CIII dimers,
and dimers lacking one or both RISP subunits
Tissue-specific decrease in CIII activity 
(~20% in the heart)
Sligthly increased OXPHOS coupling efficiency
Decreased energy expenditure
Increased fat utiliziation for energy
Fgf21 epxression




Sensitivity to metabolic stress?
Figure 12. Summary of effects of mt-Cybp.D254N variant on Bcs1l wild-type and mutant mice.
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10 CONCLUSIONS AND FUTURE PROSPECTS
CIII deficiencies are still scarcely studied among the mitochondrial diseases. This thesis 
project has extended the characterization of CIII-related disease mechanisms and 
investigated two proposed therapies in a mouse model of GRACILE syndrome. Moreover, 
we identified a novel homoplasmic mtDNA variant that can be utilized to study subtle CIII 
dysfunction or to exacerbate CIII deficiency in Bcs1lp.S78G mice and possibly in other mouse 
models of CIII deficiency. 
Study I
In study I, we showed that ketogenic diet can ameliorate a CIII deficiency-related 
hepatopathy in mice. Some studies have proposed that ketogenic diet increases 
mitochondrial biogenesis.162,167 Our results did not support this theory. Despite this, 
ketogenic diet clearly improved mitochondrial function and morphology in Bcs1lp.S78G mice. 
The mechanism of action of ketogenic diet, however, remains elusive. A dramatic shift 
in energy metabolism follows the extreme carbohydrate-restriction and high fat content 
of the ketogenic diet. Therefore, it is evident that ketogenic diet necessarily modulates 
mitochondrial function. However, which of the metabolic adaptations to ketogenic diet are 
beneficial and which perhaps harmful in mitochondrial disorders requires further studies. 
Moreover, ketogenic diet may mediate its effects via the ketone body β-hydroxybutyrate, 
which is now a well-recognized signaling molecule.250 Our transcriptomic data suggested 
that ketogenic diet affected macrophage polarization in the Bcs1lp.S78G mice. A recent study 
showed that stimulation of HCAR2 receptor with β-hydroxybutyrate attenuates acute liver 
damage via altered macrophage polarization.233 In addition, β-hydroxybutyrate modulates 
macrophage polarization via inhibition of NLRP3 inflammasome.175 β-hydroxybutyrate 
is also a direct substrate for histone β-hydroxybutyrylation251. The signaling functions of 
ketone bodies in Bcs1lp.S78G mice, without the metabolic adaptations related to carbohydrate 
restriction and high fat content, could be studied with ketone ester supplementation252.
Study II
NAD+-repletion therapies have proven beneficial in a number of preclinical models of 
various disease conditions.128 Yet, the knowledge on NAD+ repletion in different tissues 
in primary mitochondrial diseases is still very limited. We were the first to study NAD+ 
repletion in isolated CIII deficiency and in a mitochondrial hepatopathy. In contrast to 
mitochondrial myopathy models,130,131 the hepatic NAD+ depletion and the hepatopathy of 
Bcs1lp.S78G mice were refractory to the NAD+ precursor NR.  Considering the fact that the 
tryptophan is a major precursor for hepatic NAD+ biosynthesis,192 and this pathway being 
repressed in Bcs1lp.S78G mice, an alternative NAD+ repletion strategy such as the inhibition 
of ACMSD to maximize tryptophan utilization for NAD+ biosynthesis,205 could have 
proven more effective than NR. Nonetheless, the investigation of the downstream effects 
of NAD+ depletion and the linked cellular signaling events suggested that the starvation-
like metabolic state of Bcs1lp.S78G mice endogenously stimulates the very same metabolic 
adaptations that are the primary targets of NAD+-repletion therapies.
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We did not analyze in detail the effects of NR on other tissues than liver due to the lack 
of improvement in the general condition of Bcs1lp.S78G mice. Despite this, taking into 
the consideration the role of liver in maintaining circulating nicotinamide for NAD+ 
biosynthesis in extrahepatic tissues, it is possible that NR administration increased NAD+ 
concentrations in other tissues such as in skeletal muscle. 
Study III
AOXs are intriguing respiratory enzymes that most animals have lost during evolution.253 
They function as quinol overflow valves to alleviate an insufficiency of the CIII-CIV 
segment of the electron transfer. Our results showed that, when introduced into the 
CIII-deficient mice, AOX restored respiratory electron transfer in the heart. This was 
sufficient to give long-term protection from cardiomyopathy and allow near-normal 
lifespan. Our results are consistent with the heart failure of Bcs1lp.S78G mice being due to 
a primary mitochondrial cardiomyopathy, but it is also highly likely that the liver and 
kidney disease contribute to the cardiomyopathy progression. Especially, the effect of AOX 
on kidney morphology is interesting despite that it did normalize the function of this 
organ. Unexpectedly, at the end-stage, AOX had only minimal effect on the liver, the most 
affected organ in the GRACILE syndrome. It appears that the CIII deficiency was not severe 
enough in the liver of relatively old Bcs1lp.S78G mice to allow AOX-mediated respiration in 
vivo. Whether AOX affects the metabolic crisis of the juvenile period involving a more 
severe hepatic CIII deficiency and whether the AOX can rescue the early lethality in 
Bcs1lp.S78G;mt-Cybp.D254N  mice are ongoing projects in our laboratory. We are also utilizing 
AOX to study in more detail mitochondrial ROS signaling and the consequences of 
coenzyme Q pool overreduction in Bcs1lp.S78G mice.
Study IV
A stunning 5-fold difference in the lifespan of Bcs1lp.S78G mice in two closely related congenic 
substrains in two animal facilities puzzled us during the studies I-III. The difference was 
beyond explanation by any environmental differences between the two animal facilities. 
Never would we have expected that the underlying genetic difference turned out to be a 
single-nucleotide change in the only CIII subunit gene in mtDNA, mt-Cyb. Even more 
astonishing was the location of the consequent amino acid change in a segment of MT-
CYB ef loop interacting with RISP, which incorporation into CIII is compromised by Bcs1l 
mutations.
We demonstrated that the mt-Cybp.D254N variant causes a subtle restriction in the RISP head 
domain movement. The effects of mt-Cybp.D254N and Bcs1lp.S78G on CIII activity were not 
entirely additive but synergistic. Bcs1lp.S78G affects CIII activity indirectly by decreasing the 
efficacy of RISP insertion into the complex. The small number of fully assembled CIII 
dimers in Bcs1lp.S78G mutants should have a native structure. However, it is possible that 
most of the RISP in Bcs1lp.S78G mutants is in heterodimers containing only one RISP. In 
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theory and according to bacterial heterodimer models,246,247 a single-RISP CIII dimer could 
be enzymatically active and have increased sensitivity to the mt-Cybp.D254N variant. However, 
investigation of heterodimers and inter-monomer electron transfer was beyond the scope 
of study IV.
No genetic tools exist to introduce targeted mutations into the multicopy mammalian 
mtDNA. Therefore, the spontaneous homoplasmic mt-Cybp.D254N variant mouse line may 
prove a highly valuable tool. The mt-Cybp.D254N variant is not overtly pathogenic but neither 
silent. It consistently decreased cardiac CIII activity in Bcs1l wild-type mice. Moreover, in 
liver and kidney mitochondria, it decreased leak respiration and increased electron transfer 
coupling efficiency. At whole-body level, mt-Cybp.D254N decreased energy expenditure 
and most astonishingly, it induced similar hepatic Fgf21 expression as the pathogenic 
Bcs1lp.S78G mutation. According to the sequence databases, mt-Cybp.D254N is present in three-
toed sloths (Bradypus torquatus) of South America which have slow metabolism and 
extremely energy-poor diet.254 The existence of mt-Cybp.D254N in nature suggests that it might 
even be beneficial under certain circumstances.
We investigated the effect of mt-Cybp.D254N on ROS production relatively superficially in 
study IV. Our data from mouse and Rhodobacter capsulatus model, and also previous 
studies on similar mutations,245 indicate that mt-Cybp.D254N does not promote superoxide 
production at Qo site. However, in vivo, mitochondrial membrane potential and coenzyme 
Q pool redox status affect ROS production.65 Mt-Cybp.D254N potentially, as respirometry data 
indirectly suggests, affects both parameters. A topic of future studies is also the effect of the 
subtle mt-Cybp.D254N-mediated disturbance in mitochondrial bioenergetics and whole-body 
metabolism on aging or physiology under stressed conditions.
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